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Tuberculosis (TB) is the leading cause of death from a bacterial infection in humans. 
Despite its impact throughout history on humans across the globe, it remains challenging to 
diagnose and treat. This work used molecular biology and next generation sequencing to 
explore these issues. First, in a study to identify potential biomarkers of TB infection, the 
interaction between Mycobacterium tuberculosis (the causative agent of TB), the mouse 
immune system, and the murine gut microbiota was examined. The murine gut microbiota was 
observed to respond specifically to M. tuberculosis infection in several host genotypes, and 
these changes were most likely mediated by the adaptive immune system. Together, these data 
confirm that the response of the gut microbiota can be further explored for TB diagnostics. A 
second study was aimed at understanding the genetic mechanisms of resistance to a novel anti-
mycobacterial compound. Resistance was mediated through loss of function of Rv2887, a 
previously unannotated gene that was found to be a multiple antibiotic resistance repressor 
(MarR) transcriptional regulator. Analysis of the function of Rv2887 led to the identification of a 
gene regulation mechanism that could be a potential new drug target. Finally, in a third study 
the genetic basis of geographic restriction of M. africanum, a mycobacterial species that causes 
similar disease to human TB but is usually only found in West Africa, was elucidated. Despite 
conventional dogma, analysis of M. africanum using new bioinformatics tools revealed that it is 
not a separate species from M. tuberculosis. Furthermore, M. africanum is unimpaired in 
transmission or virulence compared to M. tuberculosis, thus suggesting that the geographic 
restriction may be due to host factors. Taken together, this work explores the host-pathogen 
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Chapter 1: Introduction 
 Mycobacterium tuberculosis is an acid fast bacterium that causes tuberculosis (TB), a 
devastating disease that affects one-third of the world’s population and kills 1.3 million people a 
year, mostly in developing countries [1]. After HIV, it is the second deadliest infectious agent, 
and it is a leading killer of HIV-infected patients. M. tuberculosis is spread through the aerosol 
route and primarily causes pulmonary disease, although it can spread throughout the body [1]. 
 Tuberculosis has evolved alongside its human host, and has been identified in ancient 
Egyptian and Peruvian mummies [2-4]. Despite advances in modern medicine, tuberculosis 
remains challenging and time consuming to treat. Standard tuberculosis treatment is currently 
six months long, and involves a two-month high intensity phase consisting of treatment with 
four antibiotics (isoniazid, rifampin, ethambutol, and pyrazinamide) followed by a four month 
continuation phase (treat with isoniazid and rifampin only). However, despite this combination 
therapy, drug resistance is on the rise, and in 2013, there were an estimated 480,000 cases of 
multi-drug resistant tuberculosis (MDR-TB), which is defined as bacteria that is resistant to at 
least isoniazid and rifampin. These cases require up to two years of treatment, but even under 
these conditions drug resistance is developing, and 9% of MDR-TB cases were extremely drug 
resistant (XDR), meaning that they were also resistant to second line antibiotics [1]. Worse, 
there are now reports of tuberculosis patients diagnosed with totally drug resistant (TDR) 
tuberculosis, which are resistant to all tested antibiotics, leaving patients and physicians with 
few options [5,6].  
 Not only does long treatment and developing drug resistance provide barriers to 
eradication of tuberculosis, but diagnosis also remains challenging. M. tuberculosis is slow 
growing, with a doubling time of 24 hours in culture, and thus standard culture based 
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approaches can take at least a month, even under ideal conditions [7]. Newer approaches, such 
as the Gene Xpert, use mycobacterial-specific sequences to address these issues [8]. However, 
these are limited by a lack of knowledge of the genetics of M. tuberculosis and what different 
mutations mean. 
 One new tool for uncovering genetic mechanisms is next generation sequencing. This 
provides a relatively cost effect way to analyze the nucleic acid (RNA or DNA) content of a 
sample. There are several such technologies currently available, including the Roche 454, 
Illumina HiSeq and MiSeq, ABI SOLiD, PacBio, Ion Torrent and Ion Proton[9,10]. All of these are 
based on the principle of massively parallel sequencing of millions of nucleic acid fragments and 
then using computational bioinformatics approaches to interpret the resulting reads to develop 
meaningful inferences, such as the whole genome sequence of a clinical isolate. Although 
currently too expensive to be used routinely in diagnostics, the cost of sequencing is rapidly 
decreasing, making it feasible to ask new questions about the biology of pathogens and their 
interaction with their host. 
 In this work, we used a combination of molecular biology techniques and next 
generation sequencing to analyze the interaction of M. tuberculosis with the microbiome, 
identify the target of a novel anti-mycobacterial compound, and study the genetics of Mali 
clinical isolates. Together, this data i) explores the interaction between pathogen, host, and 
resident microbial community, ii) identifies a novel mechanism of gene regulation in 
mycobacteria and iii) provides new insights into genetics of M. tuberculosis and the closely 




Chapter 2: Aerosol Mycobacterium tuberculosis Infection Causes 
Rapid Loss of Diversity in Gut Microbiota 
This work has been published in PLoS ONE, doi: 10.1371/journal.pone.0097048, with assistance 
from Dr. Emiley Eloe-Fadrosh for data analysis and figure generation. 
2.1 Abstract 
Mycobacterium tuberculosis is an important human pathogen, and yet diagnosis 
remains challenging.  Little research has focused on the impact of M. tuberculosis on the gut 
microbiota, despite the significant immunological and homeostatic functions of the 
gastrointestinal tract. To determine the effect of M. tuberculosis infection on the gut microbiota, 
we followed mice from M. tuberculosis aerosol infection until death, using 16S rRNA sequencing. 
We saw a rapid change in the gut microbiota in response to infection, with all mice showing a 
loss and then recovery of microbial community diversity, and found that pre-infection samples 
clustered separately from post-infection samples, using ecological beta-diversity measures. The 
effect on the fecal microbiota was observed as rapidly as six days following lung infection. 
Analysis of additional mice infected by a different M. tuberculosis strain corroborated these 
results, together demonstrating that the mouse gut microbiota significantly changes with M. 
tuberculosis infection.  
2.2 Introduction 
 Although the mouse immunopathologic response to TB differs from the response in 
humans, the mouse model is frequently used to study the virulence of different strains of M. 
tuberculosis, and to assess TB drug efficacy [11]. Upon aerosol infection, the bacteria promptly 
replicate in the lungs, and disseminated bacilli are observed in the spleen and liver two to four 
weeks later. Beginning at four weeks post-infection, the mouse adaptive immune system 
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achieves partial control of the infection, resulting in a plateau in bacterial burden [12]. The 
mouse will develop granuloma-like lesions in the lung and, with a high infecting dose, will 
eventually succumb to the bacteria and die. 
One aspect of TB infection that remains largely unexplored is the role of and impact on 
the resident microbiota (the microorganisms that collectively live on or in mammals). It is now 
well recognized that the gastrointestinal microbiota maintain a complex, reciprocal relationship 
with the host immune system [13-16]. Moreover, differences in fecal microbiota composition 
and functional potential have been identified in individuals with various disease states when 
compared to healthy individuals, including inflammatory bowel disease, arthritis, type 2 
diabetes, and asthma [17-19]. The gut microbiota also plays a prominent role in both enteric 
bacterial and viral infections [20-23]. However, there have been few studies focused on changes 
in the gut microbiota in response to TB, especially in the absence of antibiotics. 
At the beginning of our research, only one other study had focused on the gut 
microbiota during TB infection. Dubourg and colleagues utilized culture-dependent and -
independent methods to evaluate bacterial and fungal diversity within a single patient at a 
single time, and found that there was an impoverished community dominated by only a few 
phylotypes [24]. However, this patient had been treated with broad-spectrum antibiotics for 
four months, which can greatly alter the gut microbiota.  Another study concluded that there 
was a difference between the sputum microbial composition of TB patients and healthy controls 
[25].  Conversely, a different paper focused on human sputum samples found no difference 
between TB patients and healthy controls [26].  
 Given the interaction between the resident microbiota and the immune system, as well 
as competition among the microbiota and invading pathogens, we hypothesized that M. 
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tuberculosis would cause a shift in the gut microbiota. Here, we present a longitudinal survey 
using 16S ribosomal gene sequencing of the gut microbiota in a mouse model for TB. We 
assessed bacterial community composition and diversity prior to infection with M. tuberculosis 
CDC1551 and throughout infection until death. Further, we evaluated the gut microbiota from 
additional mice infected by a different M. tuberculosis strain (H37Rv) for comparison to the 
longitudinal study. 
2.3 Materials and Methods 
2.3.1 Ethics Statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. The Animal 
Protocol MO11M120 was approved by the Institutional Animal Care and Use Committee of the 
Johns Hopkins University, and covers all animal procedures, including time-to-death. All efforts 
were made to minimize suffering.  
2.3.2 Bacterial Strains 
Mycobacterium tuberculosis H37Rv and CDC1551 were routinely grown in Middlebrook 
7H9 broth (Fisher Scientific, Waltham, MA) supplemented with 0.5% glycerol (Sigma, St. Louis, 
MO), 0.05% Tween 80 (Sigma) and 10% oleic acid-albumin-dextrose-catalase (OADC; Fisher 
Scientific) at 37oC with agitation. 
2.3.3 Animals 
For the M. tuberculosis CDC1551 experiment, 4-6 week old female Balb/c mice were 
purchased from Charles River (Wilmington, MA). The five mice used for stool collection were toe 
tattooed for identification purposes and housed in the same cage. Mice were monitored daily as 
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part of a time-to-death experiment and were provided with gel cups broken up feed biscuits 
when they became cachectic. For the M. tuberculosis H37Rv experiment, 19-20 gram female 
Balb/c mice were purchased from Charles River. Mice were housed in cages containing 5 
animals. For each group, 3 mice were randomly selected from one cage, and 2 from another, for 
stool collection. For colony forming unit (CFU) counts of lungs and spleens, mice were 
euthanized by cervical dislocation.  
2.3.4 Stool Collection and Storage 
For stool collection, each mouse was temporarily placed alone in a clean container until 
there was approximately 0.15 g stool in the container. The mouse was removed and the stool 
collected and stored in O-ring sealed tubes (Simport, Beloeil, Canada) at -80oC. 
2.3.5 Aerosol Infection 
Mice were infected with log-phase broth cultures diluted in phosphate-buffered saline 
(PBS) using the Middlebrook inhalation exposure system (Glas-Col, Terre Haute, IN) in a single 
run. Bacterial burden was determined by sacrificing 3 mice per time point and enumerating 
CFUs on selective 7H11 plates (VWR, Radnor, PA). 
2.3.6 DNA Extraction and 16S rRNA Sequencing 
Total DNA was extracted from 0.15 grams of stool using the ZR Fecal DNA isolation kit 
(ZYMO Research Corp., Irvine, CA) with modifications including an enzymatic pre-treatment with 
mutanolysin (5000 units ml-1, Sigma) and lysozyme (100 mg ml-1, Sigma) in conjunction with 
aggressive bead beating using 0.1mm glass beads (BioSpec, Bartlesville, OK) and a bead-beater 
(BioSpec). Barcoded primers [27] were used to amplify the bacterial 16S rRNA gene region 27F-
338R from 50 ng of purified DNA using AccuPrime High Fidelity DNA polymerase (Invitrogen, 
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Grand Island, NY) in a total reaction volume of 25 μL. Reactions were run in a PTC-100 thermal 
controller (MJ Research, Waltham, MA) using the following cycling parameters: 5 min of 
denaturation at 95 °C, followed by 25 cycles of 30 s at 95 °C, 30 s at 55 °C, and 60 s at 68 °C, with 
a final extension at 72 °C for 7 min. Amplicons were quantified using the Quant-iT PicoGreen 
dsDNA assay and equimolar amounts (100 ng) of the PCR product were mixed in a single tube. 
Amplification primers and reaction buffer were removed from each sample using the AMPure 
Kit (Agencourt, Brea, CA). The purified amplicon mixtures were sequenced by 454 FLX 
pyrosequencing using 454 Life Sciences primer A by the Genomics Resource Center at the 
Institute for Genome Sciences, University of Maryland School of Medicine. 
2.3.7 16S rRNA sequence processing and analysis  
Sequences generated from pyrosequencing of bacterial 16S rRNA gene amplicons from 
all mouse experimental groups were processed using mothur, version 1.27, according to the 
standard pipeline outlined in [28,29]. Sequences were denoised, trimmed, quality and chimera 
checked using de novo uchime, and clustered into operational taxonomic units (OTUs) at 97% 
pairwise identity and aligned to the Silva reference alignment [30]. Taxonomic classifications 
were assigned using the naïve Bayesian classifier with the May 2011 release of the greengenes 
database [31]. Rarefied OTUs (randomly subsampled to normalize sequence counts) were used 
to calculate community diversity for each sample. Unweighted and weighted UniFrac distances, 
a phylogenetically-sensitive measure of beta-diversity, was used as input for the Principle 
Coordinate Analysis (PCoA), with visualizations performed using the R package vegan [32]. An 
analysis of molecular variance (AMOVA) was performed to test whether the groups were 
statistically significant. In addition, the program Metastats was used to identify differentially 
abundant OTUs between pre- and post-infection groups [33]. Network analysis to evaluate how 
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the OTUs were partitioned among samples was performed using the make_otu_network.py 
script from QIIME [34] and visualized using Cytoscape [35]. 
2.3.8 Nucleotide accession numbers  
The 16S rRNA 454 pyrosequencing data has been deposited in the GenBank Sequence 
Read Archive under accession number SRA060942.  
2.4 Results 
2.4.1 Compositional changes in the gut microbiota during M. 
tuberculosis infection 
 To study the impact of M. tuberculosis infection on the gut microbiota, we infected 
Balb/c mice with M. tuberculosis CDC1551, and monitored them until death. We collected fecal 
samples at time points prior to infection (pre-infection) and throughout infection (post-
infection), selecting for analysis three pre-infection samples as controls, as well as samples from 
the first two weeks post-infection, the last two weeks prior to death and once per month in 
between (Figures 2-1, 2-2a, and Table 2-1). The fecal microbiota was characterized by 454 
pyrosequencing of bacterial 16S rRNA gene amplicons (V1-V2 region) from the five infected 
mice. A total of 297,156 high-quality sequences were generated, corresponding to an average 
6,322 reads per sample with an average length of 250 base pairs. These sequences were 
clustered into operational taxonomic units (OTUs) at 97% pairwise identity and taxonomically 
classified using the greengenes database [31]. The most abundant genera are shown in Figure 2-
2b. 
 We further analyzed overall community diversity using the Shannon diversity index, a 
common ecological diversity measure, which takes into account both the number of species 
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(OTUs) present and their relative abundance (Figure 2-2c). There was an initial decrease in 
diversity in all mice post-infection, followed by a recovery in diversity until death or one week 
prior to death. This was true even for mouse 2, which survived 73 days longer than any of the 
other mice. These trends were also observed using the Inverted Simpson diversity index, which 
takes into account community richness, abundance, and is less sensitive to rare OTUs compared 
to the Shannon diversity index (Figure 2-3). 
2.4.2 Gut community composition and structure differ based on 
infection status 
 To identify samples with similar microbial community structure and composition, we 
implemented multidimensional cluster analysis based on the weighted and unweighted UniFrac 
distances (Figures 2-4a and 2-4b). UniFrac is a phylogenetically-aware measure of beta-diversity 
that can be used to compare OTU structure and community diversity. The weighted measure 
takes into account phylogenetic tree branch length. Both measures showed clear clustering 
among the uninfected samples taken pre-infection and the infected samples collected post-
infection. We utilized an analysis of molecular variance (AMOVA), a statistical model similar to 
analysis of variance that is used to analyze differences in genetic diversity, to test whether the 
pre-infection and post-infection samples were statistically different, and found both weighted 
and unweighted UniFrac measures were significantly different (p < 0.001). We further utilized a 
network analysis to evaluate how the OTUs were partitioned among samples, lending additional 
support for the separation of pre- vs. post-infection samples. Strikingly, the first two weeks after 
infection were found to be intermediate between the samples taken before infection and later 
in infection, with the Firmicutes distinguishing between the two conditions (Figure 2-4c)  
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We next implemented a categorical analysis to evaluate whether specific bacterial OTUs 
discriminated between pre-infection and the infected samples collected post-infection. Eighty-
eight OTUs were found to be significantly differential (q<0.01); the majority belonged to the 
Firmicutes, specifically within the order Clostridiales (Figure 2-5, Supplemental Table 2-S1) [33]. 
The bulk of these OTUs classified within the Lachnospiraceae family, 31 affiliated with the 
unclassified Lachnospiraceae OTU2087 clade, and the Ruminococcaceae family. Interestingly, all 
of these significantly different OTUs were more abundant pre-infection compared to post-
infection.  
2.4.3 Distinct changes in the gut community is independent of M. 
tuberculosis strain 
 To determine if our previous results could be replicated with a different M. tuberculosis 
strain, we collected fecal samples from a single time point (46 days post infection) from M. 
tuberculosis H37Rv infected Balb/c mice and age-matched uninfected Balb/c mice that had been 
in the same facility for the same amount of time. Each group of mice was kept in two different 
cages to rule out variations in caging conditions. As described for the previous study, the fecal 
microbiota was characterized by 454 pyrosequencing of bacterial 16S rRNA gene amplicons (V1-
V2 region) for this set of mice. A total of 148,466 high-quality sequences were generated, 
corresponding to an average 14,847 reads per sample, and were analyzed with the first 
experiment dataset to maintain consistency in OTU clustering (see Methods). The most 
abundant genera are shown in Figure 2-6. We implemented multidimensional cluster analysis 
based on the weighted and unweighted UniFrac distances and found distinct clustering between 
infected and uninfected samples, congruent with the results for the longitudinal study (Figures 
2-7a and 2-7b). Network analysis similarly confirmed these observations (Figure 2-7c). These 
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results corroborate our earlier observations of distinct clustering between infected and 
uninfected animals. 
 Additionally, we found considerable overlap in the phylogenetic affiliation of the 
differentially abundant OTUs, which discriminated between uninfected and H37Rv-infected 
samples, compared to the CDC1551 infection longitudinal study. Seventy-three OTUs were 
found to be differential using the categorical analysis (q<0.01), the vast majority similarly within 
the Lachnospiraceae and Ruminococcaceae families (Figure 2-8 and Supplemental Table 2-S2). 
Remarkably, the phylogenetic affiliations of the discriminatory OTUs mirrored those found in the 
CDC1551 infection longitudinal study and were highly abundant in the uninfected group, 
including OTU2087 (family Lachnospiraceae), OTU1995 (order Clostridiales), OTU1998 (genus 
Catabacteriaceae), OTU2159 (family Ruminococcaceae), OTU2166 (genus Clostridium), and 
OTU2176 (genus Oscillospira). However, while there was high congruence in the phylogenetic 
lineages observed between the two M. tuberculosis studies, only five OTUs specifically 
overlapped in both experiments (Appendices A and B).  
2.5 Discussion 
 We have monitored changes in the composition of the mouse gut microbiota from pre-
infection to death, and shown that there is a clear difference between the microbial 
communities of infected and uninfected mice, results that have been confirmed by the use of 
two different strains of M. tuberculosis. These changes occur by day six post aerosol infection, 
indicating that this shift is very rapid. The prompt shift in the community after aerosol infection 
suggests that the gut microbiota is modulated during TB infection and may be responding to 
host immunological changes [36]. Furthermore, there is a consistent trend in these alterations, 
with a decrease in overall community diversity and discrete shifts in specific microbial taxa, 
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despite the difference in survival time for the five mice studied. This trend occurred even in 
mouse 2, which survived 73 days longer than the other mice. Overall, we identified a number of 
OTUs significantly different between infected and uninfected mice, regardless of the infecting 
strain of M. tuberculosis. Mycobacterial DNA was not detected in any of these samples with the 
16S rRNA pyrosequencing, but PCR of the IS6110 insertion sequence, which is specific for M. 
tuberculosis, in the last sample collected prior to death identified TB in only three of the five 
mice (data not shown). We posit that the observed microbiota changes are not be mediated 
directly by the presence of M. tuberculosis in the gut, but instead represent crosstalk between 
the resident microbiota and the mucosal immune system. In fact, the minimum in diversity 
approximately corresponds to the time when the adaptive immune system begins to achieve a 
plateau in bacterial burden [37]. Thus, the loss of diversity could be a result of immune system 
activation, with a recovery once bacterial burden and immune activity have reached 
equilibrium. 
 We observed significant differences in the relative abundance of members within the 
Lachnospiraceae and Ruminococcaceae families (Clostridiales) in the two studies, with higher 
relative abundances in both the uninfected and pre-infected mice. It is known that some 
members of clusters IV and XIVa of the genus Clostridium (a genus in the Clostridiales) induce 
regulatory T cells [38]. Members of the Lachnospiracaceae have also been shown to decrease in 
abundance in inflammatory bowel disease (IBD) and colitis [39,40]. Furthermore, a recent study 
found that a decrease in abundance of OTU 2087 was correlated with exacerbated asthma [41]. 
Future work to delineate immune-modulatory members of the Clostridiales, particularly those 
members associated with regulatory T cells and which have a role in M. tuberculosis immunity, 
will be critical.  
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 While not as prominent as the differential Clostridiales OTUs, we additionally observed a 
subset of Bacteroidales OTUs differentially abundant in pre-infected and uninfected samples in 
the two studies. Bacteroides spp. have been shown to play important anti-inflammatory roles in 
inhibiting activation of the NF-κB pathway and induction of IL-10-producing T cells [15]. 
Furthermore, Bacteroides fragilis has been shown to modulate the T-helper type 1/2 (Th1/Th2) 
balance, another aspect of the immune system critical for the control of M. tuberculosis [42]. 
Further studies to characterize the relationship of specific Bacteroides species to the immune 
system are clearly needed. 
Together, our results establish that the gut microbiota of mice changes significantly 
following aerosol infection by M. tuberculosis, and these differences may be related to the 
immune signaling from lung to gut. These changes begin as early as six days post infection and 
are characterized by an initial loss in diversity, which recovers to a significantly different 
composition. During this time, there are many alterations in the relative abundance of a number 
of OTUs, most significantly a decrease in members of the Clostridiales and Bacteroidales. These 
observations have important implications for our understanding of the interplay between the 
immune system and the gut microbiota. Further investigation into the interaction of the host 
immune system and the gut microbiota could lead to a more mechanistic understanding of gut 






Figure 2-1. Bacterial burden of M. tuberculosis CDC1551 infected mice. 
M. tuberculosis colony forming units (CFUs) at day 0, 14, 28 and 56 in (A) the lungs and (B) the 




Figure 2-2. Community structure of individual M. tuberculosis CDC1551 infected mice over 
time. 
(A) Survival time in days post-infection for each mouse. (B) Phylogenetic profile of bacterial 
genera. Stacked bar charts in chronological order for each mouse of the 18 main genera 
identified based on ≥ 1% abundance present in at least two samples. Unclassified sequences are 
not shown. Black colored bars along x-axis indicate samples taken prior to infection, while red 
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colored bars indicate post-infection. Each group represents an individual mouse, followed to 
death. The mice are represented sequentially, with mouse 1 on the left, and mouse 5 on the 
right. (C) Community diversity in each sample as measured by the Shannon diversity index, 
plotted against the percent survival time.  
 
Figure 2-3. Community diversity of M. tuberculosis CDC1551 infected mice. 
Community diversity in each sample as measured by the Inverted Simpson diversity index, 




Figure 2-4. Composition of the gut microbiota significantly changes with M. tuberculosis 
CDC1551 infection. 
(A) Unweighted and (B) weighted Unifrac measures of beta-diversity visualized using Principle 
Coordinate Analysis (PCoA) following individual mice over time with M. tuberculosis CDC1551 
infection. Blue dots indicate samples collected pre-infection. Red dots indicate samples 
collected post-infection. Variance for first two component axes is shown as percent of total 
variance. An analysis of molecular variance (AMOVA) was performed to test whether the 
separation of uninfected and TB-infected samples was statistically significant. In both 
unweighted and weighted Unifrac measures, there was a statistically significant difference 
(p<0.001). (C) Network analysis of OTUs partitioned among samples, using a five sequence 




Figure 2-5. Differentially abundant OTUs identified between pre-infection and post-infection.  
OTUs are ordered by consensus taxonomic classification, with OTUs scaled by relative 





Figure 2-6. Phylogenetic profile of bacterial genera for uninfected and M. tuberculosis H37Rv 
infected mice. 
Stacked bar charts for uninfected and H37Rv-infected mice of the 16 main genera identified 
based on ≥ 1% abundance present in at least two samples. Unclassified sequences are not 
shown. The black colored bar along x-axis indicates the five uninfected mice, while the red 




Figure 2-7. Gut microbiota composition of M. tuberculosis H37Rv infected mice is significantly 
different from uninfected mice. 
(A) Unweighted and (B) weighted Unifrac measures of beta-diversity visualized using Principle 
Coordinate Analysis (PCoA) for the comparison of H37Rv-infected mice to uninfected mice at a 
single time point. Blue dots indicate samples collected pre-infection. Red dots indicate samples 
collected post-infection. Variance for first two component axes is shown as percent of total 
variance. In both unweighted and weighted Unifrac measures, there was a statistically 
significant difference (AMOVA p≤0.005). (C) Network analysis of OTUs partitioned among 




Figure 2-8. Differentially abundant OTUs identified between uninfected and M. tuberculosis 
H37Rv infected mice. 
OTUs are ordered by consensus taxonomic classification, with OTUs scaled by relative 






Mouse ID Time points sampled (days) Time of Death (day) 
1 -5, -1, 0, 6, 13, 34, 55, 75, 81 95 
2 -5, -1, 0, 6, 13, 34, 69, 95, 123, 150, 158, 162 179 
3 -5, -1, 0, 6, 13, 34, 69, 95, 102 106 
4 -5, -1, 0, 6, 13, 34, 55, 81 89 
5 -5, -1, 0, 6, 13, 34, 69, 95, 102 106 
 
Table 2-1. Time points assayed and time of death for each mouse.  
Stool samples were collected every week post-infection. From these specimens, we selected 
samples from the first two weeks post-infection, the last two weeks prior to death and once per 





Chapter 3: Interaction between M. tuberculosis, the immune 
system, and the microbiota results in specific changes and is 
mediated by the adaptive immune system 
3.1 Abstract 
 Previous work has shown a rapid and significant change in the gut microbiota of mice 
aerosol infected by Mycobacterium tuberculosis. We were interested in the mechanism behind 
these changes and hypothesized that the immune system plays a critical role in this response. To 
determine the mechanism, we infected Balb/c, Black/6, MyD88-/- and RAG-/- mice with M. 
tuberculosis and assessed changes in species and gene content in the gut microbiota through 
16S rDNA sequencing, whole genome sequencing and RNA-seq. We identified organisms and 
KEGG orthologs significantly associated with M. tuberculosis infection, as well as with changes in 
cytokine levels. Furthermore, we confirmed our previous findings, showing that the microbiota 
changes by day 10 post-infection in multiple mouse genotypes. In addition, we found that the 
microbiota of RAG-/- responds differently than the other genotypes, indicating that the changes 
detected are mediated through the adaptive immune system. Finally, we demonstrated a 
significant difference between the microbiota of M. tuberculosis infected samples and M. avium 
or M. smegmatis infected samples, suggesting that these changes are specific to M. tuberculosis. 
Taken together, we have shown that the gut microbiota of mice responds specifically to aerosol 




 The role of the microbiome in Mycobacterium tuberculosis infection remains largely 
unexplored. As discussed in chapter 2, prior to the start of our work, only three papers had been 
published on M. tuberculosis and the microbiota. We showed that the gut microbiota undergoes 
significant changes in response to aerosol M. tuberculosis infection. Since that time, in addition 
to our work, several additional papers have been published. One paper showed that the 
microbiota plays an important role in the efficacy of vaccines, including BCG, the vaccine for 
tuberculosis [43]. Another paper looked at the microbiota of the sputum, oropharynx and nasal 
respiratory tract of pulmonary tuberculosis patients and healthy controls and found changes 
with infection, particularly in the oropharynx [44]. They also found some significant changes in 
the fungi of the microbiota. A third paper compared the sputum of new, recurrent and 
treatment failure tuberculosis cases to throat swabs from healthy controls [45]. Like us, they 
found loss of diversity with tuberculosis infection. These last two papers both identified changes 
at the phyla level that were associated with M. tuberculosis. Our results were more specific, but 
overlapped many of these phyla. Thus, there is a small but growing body of literature that 
supports our findings of changes in the microbiota associated with M. tuberculosis infection. 
 Given the rapid changes we observed in our previous study, we hypothesized that the 
changes we saw were mediated by the immune system. Many studies have shown an 
interaction between the immune system and microbiota (reviewed in [46,47]). These studies 
have demonstrated that the presence of particular aspects of the microbiota influence 
development of both the innate and adaptive immune system, and dysbiosis (alterations in the 
community) results in disease [38,48,49]. 
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 As a result, we were interested in the role the immune system plays in mediating the 
interaction between the microbiota and M. tuberculosis. To address this issue, we studied 
mouse strains lacking either the innate or the adaptive immune system and compared them to 
wild-type strains. We analyzed changes in the microbial composition in terms of both bacterial 
species and gene content through 16S rDNA sequencing, whole genome sequencing and RNA-
seq. We confirmed our previous findings of changes in the microbiota in response to M. 
tuberculosis infection and showed that these changes are specific to M. tuberculosis. 
Furthermore, we demonstrated that the microbiome of mice lacking B and T cells responds 
differently to the microbiome of other mice, suggesting that the adaptive immune system 
mediates these changes.  
3.3 Materials and Methods 
3.3.1 Bacterial Strains 
Mycobacterium tuberculosis CDC1551, Mycobacterium smegmatis mc2155 and 
Mycobacterium avium were routinely grown in Middlebrook 7H9 broth (Fisher Scientific, 
Waltham, MA) supplemented with 0.5% glycerol (Sigma, St. Louis, MO), 0.05% Tween 80 (Sigma) 
and 10% oleic acid-albumin-dextrose-catalase (OADC; Fisher Scientific) at 37oC with agitation. 
3.3.2 Animals 
4-6 week old female Balbc/J, C57BL/6J, Rag1tm1Mom, and B6.129P2(SJL)-Myd88
tm1.1Defr/J 
mice were purchased from Jackson Laboratory (Bar Harbor, ME). Mice used for stool collection 




3.3.3 Stool collection and storage 
For stool collection, each mouse was temporarily placed alone in a clean container until 
there was approximately 0.15 g stool in the container. The mouse was removed and the stool 
collected and stored in O-ring sealed tubes (Simport, Beloeil, Canada) with 1mL RNAlater (Life 
Technologies, Grand Island, NY) at 4 oC overnight. RNAlater was then removed and stool was 
stored  at -80oC. 
2.3.4 Aerosol Infection 
Mice were infected with log-phase broth cultures of bacteria diluted to OD 0.15 in 
phosphate-buffered saline (PBS) using the Middlebrook inhalation exposure system (Glas-Col, 
Terre Haute, IN). Bacterial burden was determined by sacrificing mice per Table 3-1 and 
enumerating CFUs. M. tuberculosis and M. avium were grown on selective 7H11 plates (VWR, 
Radnor, PA), while M. smegmatis was grown on 7H10 plates (VWR, Radnor, PA). 
2.3.5 Determination of cytokine levels 
Lungs or spleens were harvested from mice and put into O-ring tubes containing 1mL 
PBS and immediately flash-frozen in liquid nitrogen then stored at -80oC. Organs were thawed 
on ice and bead-beaten three times for 30 seconds with 2mm glass beads. Supernatent was 
filtered through 0.22µm cellulose acetate spin filters (Costar). Samples were run on a Luminex 
(luminex Corporation, Austin, TX) using a custom Milliplex kit from EMD Millipore Corporation 
(Billerica, MA). 
2.3.6 RNA and DNA isolation 
Two stool pellets were washed with 1mL ice cold PBS(Cellgro), then 300µL of TE-SDS 
(Sigma, St. Louis, MO), 500µL of TE-saturated phenol (Sigma), and 0.3g of 0.1mm glass beads 
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(BioSpec, Bartlesville, OK) was added. Samples were bead-beaten (Biospec) for 2 minutes then 
spun at 12,000 rpm for 5 minutes at 4oC. Phenol-chloroform-isoamyl alcohol (Sigma) was added 
to the aqueous phase in a new RNase-free tube (Ambion) and the sample was spun at 12,000 
rpm for 5 minutes at 4oC. The aqueous phase was moved to a new RNase-free tube and nucleic 
acid was precipitated with 3M sodium acetate (Ambion) and isopropanol (Sigma). The sample 
was spun at 10,000 rpm for 5 minutes at 4oC and the pellet washed with 70% ethanol, spun, and 
resuspended in RNase-free water. The concentration was measured on a Nanodrop and diluted 
to at most 50µg in 50µL. RNA and DNA were then separated and purified using the QIAgen 
Allprep RNA/DNA mini kit (Qiagen). 
2.3.7 Sequencing 
16S rDNA sequencing and whole genome sequencing were performed as described in [50] while 
RNA-seq was performed as described in [51]. 
2.3.8 Nucleotide accession numbers 
Data has been deposited in GenBank as a BioProject and can be accessed using accession 
number PRJNA219721 (http://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA219721). 
2.3.9 16S rDNA analysis 
Reads were processed as described in [50] and OTU picking was performed using QIIME 
1.6.0 with the may2013 greengenes database. Gene content predictions were made using 
PICRUSt [52]. For comparisons with the data from [53], all reads were run through the RDP 
classifier version 2.8 [31]. 
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2.3.10 Whole genome sequencing analysis 
 Reads were cleaned as described in [50] and then run through HUMAnN [54]or 
MetaPhlAn v2.0 [55]. 
2.3.11 RNA-seq analysis 
 Reads were cleaned as described in [51] and run through HUMAnN [54]. Genes were 
sum-normalized and then Witten-Bell smoothing was performed [51]. Genes that did not have 
an abundance of at least 0.00001 in at least two samples were filtered, and then a log 
transformed ratio of the RNA counts to the counts from the HUMAnN whole genome 
sequencing reads was calculated. These ratios were used for all subsequent analyses. Limma 
was used to identify changes in expression compared to day -3.  
2.3.12 Identification of associations 
 Associations between infecting organism and relative abundance were determined 
using MaAsLin [56], controlling for cage. NMDS plots were generated using BreadCrumbs 
(https://bitbucket.org/biobakery/breadcrumbs). P-values on the NMDS plots were calculated on 
sum-normalized data using the adonis method in vegan [32] using Euclidean distances, and 
adjusted using the p.adjust in R.  
3.4 Results 
3.4.1 Some OTUs are correlated with M. tuberculosis burden and 
cytokine level, regardless of host genetics 
 Given the previous observations of rapid changes induced in the gut microbiota after 
aerosol infection with M. tuberculosis, we hypothesized that the immune system is mediating 
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the changes in the microbiota [53]. In order to address this hypothesis and analyze the role of 
the immune system in this interaction, we focused on four mouse genotypes (Table 3-1). One 
was Rag1tm1Mom (hereafter abbreviated RAG
-/-). Rag1 (recombination-activating gene) is a crucial 
part of VDJ recombination and the development of B and T cell receptors, and as a result, these 
mice lack both B and T cells, and thus a functional adaptive immune system [57]. The second 
mouse strain we studied was B6.129P2(SJL)-Myd88tm1.1Defr/J (hereafter abbreviated MyD88-/-). 
MyD88 is an adaptor protein critical for signaling through Toll-like receptors, and as a result 
these knockout mice lack an innate immune system. [57]. Both of these mice were developed on 
a C57BL/6J background, and so the wild-type strain (hereafter referred to as Black/6) was 
included as a control. Finally, we included Balbc/J (hereafter referred to as Balb/c) as a positive 
control because this strain was used in our previous studies (chapter 2, [53]). Mice were either 
infected with M. tuberculosis CDC1551, or left as uninfected controls. In addition, to address 
whether the changes we saw were specific to M. tuberculosis, we infected three Balb/c mice 
with M. avium and three Black/6 mice with M. smegmatis. M. avium is a slow growing 
opportunistic mycobacterial pathogen while M. smegmatis is a non-pathogenic fast-growing 
mycobacterial strain frequently used to study mycobacterial genomics [58,59]. Figure 3-1 shows 
how these different bacteria grow in the different mouse genotypes. 
 Stool samples were collected from pre-infection to one month post-infection (Table 3-
1). By three weeks, the adaptive immune had started to respond to M. tuberculosis infection in 
wild-type mice (as evidence by the plateau in bacterial growth in Figure 3-1) and by four weeks 
all infected knock-out mice were close to death and had to be sacrificed early. We isolated RNA 
and DNA from these stool samples and performed 16S rDNA sequencing, whole genome 
sequencing, and RNA-seq (Table 3-1). From this data, we were able to determine which 
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organisms were present in the microbiota as represented by OTUs (operational taxonomic 
units), the functional content of the microbiota, and the changes in gene expression. 
 We first wanted to know whether there were any correlations between the relative 
abundance of a particular OTU or functional category and the amount of M. tuberculosis present 
in the mouse (represented by colony forming units, or CFUs). Thus, we took the average of the 
OTUs or KEGG orthologs present at each timepoint with CFU counts and used MaAsLin to 
identify any correlations. MaAsLin is a tool developed by the Huttenhower lab that can identify 
associations between metadata and microbial species or gene abundances [56]. Supplemental 
Table 3-S1 lists the significant OTUs and KEGG orthologs associated with M. tuberculosis CFU 
count. For both 16S and whole genome sequencing data, all OTUs significantly associated with 
bacterial burden in the spleen were also significantly associated with bacterial burden in the 
lungs, or had an adjusted p-value of 0.052 in the lung. Most of the significant OTUs from 16S 
rDNA sequencing were in the order Clostridiales, with the exception being the most significant 
OTU in the spleen, which was in order RF39 of the Mollicutes class. An OTU in the Adlercreutzia 
genera was the most significantly associated OTU in the lung (and was identified in the studies in 
chapter 2), but 21 Firmicutes and one Tenericutes were also significant in the lung. Likewise, for 
the OTUs identified through whole genome sequencing, all OTUs significantly associated with 
spleen CFU were also significantly associated with lung CFU. Unlike for 16S, these OTUs were all 
in the phyla Actinobacteria, particularly Enterorhabdus caecimuris. Spleen forming virus was also 
associated with lung bacterial burden. These OTUs may differ from the 16S rDNA sequencing 
results because we identified fewer OTUs in our whole genome sequencing data (see below). 
Finally, three KEGG orthologs were associated with CFU burden in the lungs when analyzing DNA 
– a transporter, an aminopeptidase and a permease (Supplemental Table 3-S1). When taking 
gene expression into account through RNA-seq, two different KEGG orthologs were associated 
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with CFU burden in the lungs – a hydrolase and an unannotated group (Supplemental Table 3-
S1). Taken together, this suggests that specific elements of the microbiota are changing in 
response to M. tuberculosis infection, regardless of mouse genotype. 
 In addition to the bacterial burdens of these mice, we also determined the amount of 
IFNγ, IL-10, IL-12(p40), TNFα, IL-17, IL-1β, IL-2 and IL-6 in the lungs and spleen (Figure 3-2). 
Similar to our analysis of the correlation between M. tuberculosis CFU and the microbiota, we 
used MaAsLin to identify OTUs or KEGG orthologs associated with cytokine levels (Supplemental 
Table 3-S2). Very few OTUs were significantly correlated with any cytokine: an OTU in the order 
Clostridiales and two viruses were associated with IL-10 levels in the lungs, and an Enterococus 
genera OTU was associated with IFNγ levels in the lungs. In contrast, in the DNA analysis two 
KEGG orthologs associated with lung IFNγ levels, eleven with lung IL-10, and 28 with spleen IL-
1β. In the RNA-seq analysis, three KEGG orthologs were associated with lung TNFα levels, one 
with spleen IL12p40 and one with spleen IFNγ. Thus, we find evidence across mouse genotypes 
of the microbiota responding to certain aspects of the immune system. 
3.4.2 Correlation between OTU composition from 16S rDNA sequencing, 
mouse genotype, and mycobacterial infection 
 We were first interested in how this experiment compared to our previous analyses 
(chapter 2, [53]). Several parameters were different between this experiment and previous 
work. First, in order to obtain the knock-out mice, we changed vendors from Charles River 
Laboratories to the Jackson Laboratory. The source of mice has previously been shown to have 
an effect on microbial composition [60]. In addition, in order to isolate RNA for RNA-seq, we 
changed our nucleic acid isolation protocol (see methods). Finally, a different 16S variable 
region was sequenced. To determine how these changes affected the microbiota, we compared 
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our previous data and the 16S data from the Balb/c mice from this experiment. We used RDP to 
pick OTUs for all samples and then graphed them on a NMDS plot (Figure 3-3)[31]. The samples 
from chapter 2 (Experiment 1 and 2) separated from the samples from this experiment 
(Experiment 3). This indicated that our Balb/c baseline was significantly different, making it 
difficult to compare directly to our previous results. 
 This difference was also evident when we look at the OTU composition of our samples 
(Figure 3-4). Compared to our previous studies, the differences between M. tuberculosis 
infected and uninfected Balb/c samples was no longer as clear. However, our new data did 
confirm that there are differences in the microbial composition of the different mouse 
phenotypes, such as the high proportion of Verrucomicrobia in uninfected RAG-/- samples 
compared to uninfected samples from the other backgrounds. Interestingly, this OTU increases 
in abundance with infection of Black/6 and MyD88-/- mice and is significantly associated with M. 
tuberculosis infection in Black/6 mice (Supplemental Table 3-S3). 
 Caging effects have been reported in mouse microbiota studies, although we did not see 
them in our previous work [61,62]. However, since this could provide a major confounding 
effect in this experiment, we separated each group of five mice into two cages. We looked at 
the pre-infection timepoints for all mice, separating them by mouse genotype, and found no 
significant caging effect, with the nonsignificant exception of the Black/6 mice later infected by 
M. smegmatis (Figure 3-5). This was also true for the whole genome sequencing and functional 
content analyses (data not shown). Thus, in these experiments, we did not have a caging effect. 
 When we compared all samples together, we found that most variation was in mouse 
genotype (Figure 3-6), with the Balb/c samples separating from the other genotypes (which 
were on a Black/6 background). As a result, we then looked at each genotype separately. In this 
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experiment, the difference between all M. tuberculosis infected and uninfected Balb/c samples 
was not significant (Figure 3-7a and b). However, from these plots, it appeared that much of the 
overlap was in the early post-infection timepoints (days 1-7). Thus, we separated the timepoints 
into early post-infection (first week), late post-infection(last week of experiment, when adaptive 
immune system has begun to respond and knockout mice are close to death) and middle 
(everything in between) (see Table 3-1). When we removed the early post-infection timepoints, 
the difference between infected and uninfected M. tuberculosis samples became significant, 
similar to our previous observations (Figure 3-7c and d). The delayed change compared to 
previous observations is most likely due to the altered microbial composition of these mice 
(Figure 3-4). Nevertheless, by day 10 the gut microbiota is significantly different between M. 
tuberculosis infected and uninfected Balb/c mice. 
 We next focused on the other mouse genotypes. Infected and uninfected Black/6 
samples were significantly different, even with the early timepoints included (Figure 3-8). 
Likewise, MyD88-/- samples were significant with and without the early timepoints, suggesting 
that the innate immune system is not required to mediate this response (Figure 3-9). In 
contrast, RAG-/- samples were not significantly different with infection, suggesting that the 
changes do require the adaptive immune system (Figure 3-10). 
 Given these significant changes, for each genotype we looked at which OTUs were 
significantly different between uninfected and M. tuberculosis infected samples using MaAsLin 
(Supplemental Table 3-S3). No OTUs were significant in all genotypes (maroon section of Figure 
3-11). However, 3 OTUs were significant in Balb/c, Black/6 and MyD88-/- with early timepoints 
removed, when all three mouse genotypes were significantly different (light blue section of 
Figure 3-11b). These three OTUs were an OTU in the Adlercreutzia genera in the Actinobacteria 
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phyla, an OTU in the order RF39 in the Tenericutes phyla, and an OTU in the family S24-7 in the 
Bacteroidetes phyla. The first was also significant when looking for correlations with M. 
tuberculosis CFU, and the second was very closely related to another OTU from that analysis. 
Thus, there appears to be a strong association between Adlercreutzia and M. tuberculosis 
infection. 
3.4.3 Correlation between whole genome sequencing OTU composition, 
mouse genotype, and mycobacterial infection 
 In addition to OTU data from 16S rDNA sequencing, we obtained whole genome 
sequencing data for a subset of timepoints. We used MetaPhlAn to predict which OTUs were 
present [55]. Unfortunately, MetaPhlAn was developed for the human microbiome, and was 
only able to identify 150 unique OTUs in our dataset (Figure 3-12). This is in contrast to the 
1,210 identified through 16S rDNA sequencing. As a result, the composition of these samples 
was very different from that predicted by 16S rDNA sequencing. For example, although 
MetaPhlAn gave us relative abundance data for viruses and eukaryotic organisms, which were 
missing from our 16S sequencing data, some bacterial phyla detected by 16S sequencing were 
missing from this analysis, such as the Tenericutes, some of which were associated with 
infection (Figure 3-4 and Figure 3-12). With these reduced samples and reduced number of 
OTUs, although there was still a significant difference between mouse genotypes, the difference 
between M. tuberculosis infected and uninfected samples was no longer significant for any 
mouse genotype, even with the early timepoints removed (Figure 3-13 to Figure 3-17). 
Furthermore, of the few OTUs significantly associated with infection status, none were 
significant in more than one genotype (Supplemental Table 3-S4, Figure 3-18). In addition, no 
OTUs were significant in both 16S rDNA and MetaPhlAn analysis (Supplemental Table 3-S3 and 
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3-S4). Thus, in our data set, 16S sequencing provides better resolution, although the whole 
genome sequencing data does follow a similar trend to the 16S. Removing early timepoints from 
Balb/c mice makes the difference between infected and uninfected more significant and Black/6 
and MyD88-/- are almost significant while RAG-/- is not (Figure 3-14 to Figure 3-17). This 
corroborates our observations that the changes in the gut microbiota become more significant 
with time and that lack of an adaptive immune system eliminates these changes. 
3.4.4 Correlation between microbiota functional content measured by 
16S rDNA sequencing, mouse genotype, and mycobacterial infection 
 Given the changes in microbial composition with M. tuberculosis infection, we were 
interested in whether the functional capabilities of the microbiome also changes. We used 
PICRUSt to predict functional content from our 16S data. PICRUSt is a tool that uses OTUs 
identified through 16S rDNA sequencing to estimate the relative abundance of gene families 
[52]. When initially plotting PICRUSt results, 31 samples were clearly different from the others 
and appeared as outliers with much higher NMDS values than any other sample. 3 of these were 
from MyD88-/-, 2 from RAG-/-, and the rest from Balb/c. Since this was not seen in the 16S data, 
we concluded that they were artifacts of the prediction algorithm, perhaps because it was 
optimized for human and not mouse microbiota. Thus, these samples were removed from 
further analysis of PICRUSt data. 
 These data provided a different picture to the changes seen at OTU level (Figure 3-19 to 
Figure 3-24). Although the difference between genotypes is significant, this is largely due to 
differences between RAG-/- and the other genotypes (Figure 3-19). Balb/c was not significantly 
different between M. tuberculosis infected and uninfected samples, even with the early 
timepoints removed, but all other genotypes, including RAG-/-, were significantly different, 
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especially with the early timepoints removed (Figure 3-20 to Figure 3-23). However, when 
looking at KEGG orthologs significantly associated with infection, RAG-/- had no significant 
features and Balb/c only had one, while Black/6 and MyD88-/- had 239 and 178 respectively, 175 
of which were shared (Supplemental Table 3-S5, Figure 3-24). Thus, M. tuberculosis infection has 
an effect on gene content as predicted from 16S sequencing, but this change is different from 
that seen at the OTU level. Nevertheless, we do still see the pattern from the OTU analysis of 
RAG-/- changes being different from Black/6 and MyD88-/-, again suggesting a role for the 
adaptive immune system in mediating these changes. 
3.4.5 Correlation between microbiota functional content measured by 
whole genome sequencing, mouse genotype, and mycobacterial 
infection 
 In addition to the functional content predictions from PICRUSt, we used HUMAnN to 
make predictions about the gene content from our whole genome sequencing data [54]. Similar 
to previous analyses, there was a significant difference between genotypes (Figure 3-25). Only 
Balb/c with early timepoints removed and Black/6 samples were significantly different between 
M. tuberculosis infected and uninfected samples, although as with our other analyses, removing 
the early post-infection timepoints decreased the adjusted p-values for all genotypes (Figure 3-
26 to Figure 3-29). However, very few KEGG orthologs were significantly associated with 
infection and there was no overlap in significant features between genotypes (Supplemental 
Table 3-S6, Figure 3-30). Furthermore, no significant KEGG orthologs from HUMAnN overlapped 
with significant orthologs from the PICRUSt analysis. Thus, although functional content can 
differentiate between M. tuberculosis infected and uninfected samples background, at least in 
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the Black/6 background, the overall genetic content seems to undergo fewer changes than at 
the OTU level. 
3.4.6 Association between gut gene expression and M. tuberculosis 
infection 
 The presence of a gene in DNA does not give any indication of the expression of that 
gene, and thus although there were few changes at the DNA level, we also looked for changes in 
the RNA level. We used HUMAnN to predict the relative abundance of KEGG orthologs from our 
RNA-seq data, normalized the abundances using our HUMAnN whole genome sequencing data, 
and calculated fold change expression from pre-infection. Supplemental Figure 3-S1 shows all 
KEGG orthologs identified as significantly changed from day -3 in at least one timepoint (data 
also listed in Supplemental Table 3-S7). As in the PICRUSt analysis, there was very little overlap 
between mouse genotypes (Figure 3-31). One KEGG ortholog was shared by the knockout mice, 
12 by Black/6 and MyD88-/-, and two between the wild-type strains. However, like at the DNA 
level, Black/6 had the most orthologs identified as significant (Supplemental Figure 3-S1b), and 
the most overlap was between Black/6 and MyD88-/-, suggesting that the response of MyD88-/- 
microbiota to infection is more like wild-type than RAG-/- microbiota, an observation echoed at 
the OTU level. 
3.4.7 The changes in gut microbial composition and gene content are 
specific to M. tuberculosis 
 One important question is whether the changes that we observed were specific to M. 
tuberculosis or were the result of a more generalized response to infection. To address this 
question, we used wild-type mice infected with other mycobacterial species (Table 3-1). One 
38 
 
control group we used was Black/6 mice infected by M. smegmatis. Unfortunately, the M. 
smegmatis cage was the only one with a potential caging effect (Figure 3-5b), which can be seen 
in the relative abundances even in pre-infection for these mice (Figure 3-4). As a result, M. 
smegmatis infected samples were significantly different from uninfected samples when 
comparing the relative abundances of OTUs from 16S rDNA sequencing after removing early 
timepoints (Figure 3-32). However, M. smegmatis infected and uninfected samples were not 
significantly different in any other analysis (Figure 3-32 and 3-33). Thus, although there may 
have been a caging effect, it was not enough to differentiate these samples from the uninfected 
mice in most analyses. In contrast, M. smegmatis-infected samples were significantly different 
from M. tuberculosis-infected samples in all analyses (Figure 3-34 and 3-35). Thus, the 
microbiota seems to be responding differently to M. tuberculosis infection than to M. 
smegmatis infection, suggesting the changes we saw were not due to a generalized activation of 
the immune system. 
 The other group we analyzed was Balb/c mice infected with M. avium. Although M. 
avium was not cleared from the mouse (Figure 3-1a), there was no significant difference 
between M. avium infected and uninfected sample in the 16S rDNA analyses, although whole 
genome sequencing (both OTU and functional content) was significant (Figure 3-36 and 3-37). In 
contrast, in all analyses there was a highly significant difference between M. tuberculosis and M. 
avium infected samples (Figure 3-38 and 3-39), confirming the findings with M. smegmatis and 
suggesting that the differences we described above were specific to M. tuberculosis. 
3.5 Discussion 
 Our previous work showed that there was a significant change in the gut microbiota of 
Balb/c mice in response to M. tuberculosis infection (Chapter 2; [53]). Here we have confirmed 
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those results and showed that despite an altered microbial composition in uninfected mice as a 
result of changes in experimental design, there was a significant change in the gut microbiota of 
Balb/c as measured by 16S rDNA sequencing by day 10 (Figure 3-7). Furthermore, these changes 
also occurred in Black/6 and MyD88-/- mice, showing that these changes are not specific to 
Balb/c mice (Figures 3-8 and 3-9). In contrast, there was not a significant difference in RAG-/- 
mice, indicating that the adaptive immune system plays a role in mediating these changes 
(Figure 3-10). Interestingly, the changes in the other mouse genotypes are occurring before the 
adaptive immune system begins to control the infection (Figures 3-1 and 3-7 through 3-9), 
suggesting that the baseline microbiota also plays role. These observations were echoed in our 
whole genome sequencing data, despite a paucity of detected OTUs (Figures 3-14 through 3-18). 
 From our whole genome sequencing data, Enterorhabdus caecimuris was identified as 
being significantly associated with M. tuberculosis CFU counts in both the lungs and spleens. E. 
caecimuris are gram positive non-spore-forming rods that were isolated from a mouse model of 
intestinal inflammation and thus may have some interaction with the immune system [63]. An 
OTU identified from 16S rDNA sequencing as being associated with M. tuberculosis CFU counts 
was in the genera Adlercreutzia. This genera has also been identified in humans, and was 
significantly associated with infection in our previous studies, and in all mouse genotypes in this 
study except RAG-/- (which does not undergo microbiota changes with infection) [64,65]. Thus, 
this OTU may be a potential biomarker of M. tuberculosis infection in patients with an intact 
adaptive immune system. 
 In addition to changes at the OTU level, this data enabled us to look at changes in gene 
content and expression. Only Black/6 mice showed significant changes in response to M. 
tuberculosis infection in both 16S rDNA and whole genome sequencing data, but MyD88-/- and 
40 
 
RAG-/- mice were also significantly changed in 16S rDNA sequencing (Figure 3-19 through 3-30). 
Interestingly, in the PICRUSt predictions and RNA-seq data MyD88-/- and Black/6 mice shared the 
most significantly changed KEGG orthologs, supporting the OTU results that the changes in 
response to infection are mediated by the adaptive immune system (Figures 3-24 and 3-31). 
These significant KEGG orthologs spanned a range of functions, including dehydrogenases, DNA 
polymerase, and ribosomal proteins, suggesting that there is not a specific pathway that is 
altered. 
 Taken together, both the 16S rDNA sequencing and whole genome sequencing data 
indicate that the microbiome of RAG-/- mice responds differently to M. tuberculosis infection 
compared to the other genotypes, both in OTU composition and gene content. There is growing 
evidence of a strong association between the microbiota and the adaptive immune system, and 
this interaction may play a role in M. tuberculosis infection [13,46,60]. The fact that the changes 
we observed are mediated by the adaptive immune system is of particular concern in patients 
with a compromised adaptive immune system, such as patients infected with the Human 
Immunodeficiency Virus (HIV). M. tuberculosis is a leading killer of HIV patients, and there is 
evidence that the microbiota plays a role in susceptibility to HIV [23,66-69]. Furthermore, the 
microbiota is disrupted by HIV infection [70-73]. Thus, given our findings, more work needs to 
be done on elucidating the interaction between the microbiota, HIV and other disease that 
suppress the immune system, and M. tuberculosis. 
 Our analysis of M. smegmatis and M. avium infected mice revealed that the microbiota 
does not change at the OTU or gene content level in response to aerosol infection with these 
mycobacteria, indicating that the changes we detected are specific to M. tuberculosis and are 
not just the result of an activation of the immune system (Figure 3-32 through 3-39). M. 
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tuberculosis induces a unique immune response compared to many other pathogens, and given 
the fact that the immune system is mediating the microbiota changes, as evidenced by that lack 
of change in OTUs in RAG-/- mice, these changes may be useful as biomarkers of M. tuberculosis 
infection [12]. Thus, here we have shown that the gut microbiota specifically responds to 
aerosol M. tuberculosis infection by day 10 post-infection at both the OTU and gene content 
levels. These changes are less pronounced in RAG-/- mice, especially in terms of changes in OTU 
composition, suggesting that the adaptive immune system plays a role in mediating this 
interaction between M. tuberculosis and the gut microbiota. 
3.6 Figures 
 
Figure 3-1. Bacterial burden in lungs and spleen. 
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Colony forming units (CFU) in A) lungs and B) spleen. 
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Figure 3-2. Lung and spleen cytokine levels. 
Levels of each cytokine in each mouse genotype, M. tuberculosis (Mtb) infected or uninfected. 
The limit of detection for each cytokine is indicated with a dotted line. 
 
Figure 3-3. NMDS plot of all Balb/c uninfected or M. tuberculosis infected samples from all 
experiments.  
Points are colored by experiment and shaped by infection status. Experiment 1 was a 
longitudinal study following 5 mice from pre-infection to death. Experiment 2 was a single 
timepoint comparing 5 infected mice to 5 age-matched uninfected mice. (Published in [53]). 
Experiment 3 was the new experiment following different mouse genotypes for one month 






Figure 3-4. Relative abundance of OTUs identified by QIIME from 16S sequencing.  
Each bar represents a different timepoint. Each graph is a different mouse. A blue line below a 
bar indicates the sample was uninfected, while a red line indicates M. tuberculosis infected, a 
green line indicates M. avium infection and a turquoise line indicates M. smegmatis infected. 




Figure 3-5. No significant caging effect was detected in this experiment. 
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NMDS plots of OTUs predicted by QIIME from 16S sequencing data in pre-infection timepoints 
for (A) Balb/c (B) Black/6 (C) RAG -/- and (D) MyD88-/-. Points are colored by cage and shaped by 
timepoint. P values are for cage number as calculated by adonis in Vegan, stratified by mouse 
number. 
 
Figure 3-6. Gut microbial composition as assessed by QIIME from 16S sequencing is 
significantly different between mouse genotypes. 
All samples from 16S sequencing, colored by genotype and shaped by infection status. P value is 




Figure 3-7. Gut microbial composition of Balb/c mice, as predicted by QIIME from 16S 
sequencing, changes by day 10 post-infection in response to M. tuberculosis infection. 
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Balb/c 16S sequencing samples colored by infection status and shaped by timepoint. A) All 
Balb/c samples. B) Balb/c samples with M. avium infected mice removed. C) Balb/c samples with 
early post-infection timepoints removed. D) Balb/c samples with early post-infection samples 
and M. avium infected mice removed. P values are for infecting organism as calculated by 




Figure 3-8. Gut microbial composition of Black/6 mice, as predicted by QIIME from 16S 
sequencing, changes in response to M. tuberculosis infection. 
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Black/6 16S sequencing samples colored by infection status and shaped by timepoint. A) All 
Black/6 samples. B) Black/6 samples with M. smegmatis infected mice removed. C) Black/6 
samples with early post-infection timepoints removed. D) Black/6 samples with early post-
infection samples and M. smegmatis infected mice removed. P values are for infecting organism 
as calculated by adonis in Vegan, and stratified by cage number. Adjusted P-value was calculated 
using FDR. 
 
Figure 3-9. Gut microbial composition of MyD88-/- mice, as predicted by QIIME from 16S 
sequencing, changes in response to M. tuberculosis infection. 
MyD88-/- 16S sequencing samples colored by infection status and shaped by timepoint. A) All 
MyD88-/-samples. B) MyD88-/-samples with early post-infection timepoints removed. P values 
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are for infecting organism as calculated by adonis in Vegan, and stratified by cage number. 
Adjusted P-value was calculated using FDR. 
 
Figure 3-10. Gut microbial composition of RAG-/- mice, as predicted by QIIME from 16S 
sequencing, does not change in response to M. tuberculosis infection. 
RAG-/- 16S sequencing samples colored by infection status and shaped by timepoint. A) All RAG-/-
samples. B) RAG-/-samples with early post-infection timepoints removed. P values are for 
infecting organism as calculated by adonis in Vegan, and stratified by cage number. Adjusted P-






Figure 3-11. Overlap between genotypes in OTUs from 16S sequencing significantly different 
between M. tuberculosis infected and uninfected samples. 
Venn diagram of overlaps of significant OTUs for each genotype with all timepoints (A) or with 
early timepoints removed (B). 
 
Figure 3-12. Relative abundance of OTUs identified by MetaPhlAn from whole genome 
sequencing data. 
Each bar represents a different timepoint. Each graph represents a different mouse. A blue line 
below a bar indicates the sample was uninfected, while a red line indicates M. tuberculosis 
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infected, a green line indicates M. avium infection and a turquoise line indicates M. smegmatis 
infected. The relative abundance colors are based on phyla. 
 
Figure 3-13. Gut microbial composition as predicted by MetaPhlAn from whole genome 
sequencing is significantly different between mouse genotypes. 
All samples from 16S sequencing, colored by genotype and shaped by infection status. P value is 




Figure 3-14. Gut microbial composition of Balb/c mice, as predicted by MetaPhlAn from whole 
genome sequencing, does not respond to mycobacterial infection. 
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Balb/c whole genome sequencing samples colored by infection status and shaped by timepoint. 
A) All Balb/c samples. B) Balb/c samples with M. avium infected mice removed. C) Balb/c 
samples with early post-infection timepoints removed. D) Balb/c samples with early post-
infection samples and M. avium infected mice removed. P values are for infecting organism as 





Figure 3-15. Gut microbial composition of Black/6 mice, as predicted by MetaPhlAn from 
whole genome sequencing, does not respond to mycobacterial infection. 
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Black/6 whole genome sequencing samples colored by infection status and shaped by 
timepoint. A) All Black/6 samples. B) Black/6 samples with M. smegmatis infected mice 
removed. C) Black/6 samples with early post-infection timepoints removed. D) Black/6 samples 
with early post-infection samples and M. smegmatis infected mice removed. P values are for 
infecting organism as calculated by adonis in Vegan, and stratified by cage number. Adjusted P-
value was calculated using FDR. 
 
Figure 3-16. Gut microbial composition of MyD88-/- mice, as predicted by MetaPhlan from 
whole genome sequencing, does not respond to M. tuberculosis infection. 
MyD88-/-whole genome sequencing samples colored by infection status and shaped by 
timepoint. A) All MyD88-/- samples. B) MyD88-/- samples with early post-infection timepoints 
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removed. P values are for infecting organism as calculated by adonis in Vegan, and stratified by 
cage number. Adjusted P-value was calculated using FDR. 
 
Figure 3-17. Gut microbial composition of RAG-/- mice, as predicted by MetaPhlAn from whole 
genome sequencing, does not respond to M. tuberculosis infection. 
RAG-/-whole genome sequencing samples colored by infection status and shaped by timepoint. 
A) All RAG-/- samples. B) RAG-/- samples with early post-infection timepoints removed. P values 
are for infecting organism as calculated by adonis in Vegan, and stratified by cage number. 






Figure 3-18. Overlap between genotypes in OTUs from whole genome sequencing significantly 
different between M. tuberculosis infected and uninfected samples. 
Venn diagram of overlaps of significant OTUs for each genotype with all timepoints (A) or with 
early timepoints removed (B). 
 
Figure 3-19. Gut gene content as predicted by PICRUSt from 16S sequencing is significantly 
different between mouse genotypes. 
All samples from 16S sequencing, colored by genotype and shaped by infection status. P value is 




Figure 3-20. Gut gene content of Balb/c mice, as predicted by PICRUSt from 16S sequencing, 
does not respond to mycobacterial infection. 
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Balb/c 16S sequencing samples colored by infection status and shaped by timepoint. A) All 
Balb/c samples. B) Balb/c samples with M. avium infected mice removed. C) Balb/c samples with 
early post-infection timepoints removed. D) Balb/c samples with early post-infection samples 
and M. avium infected mice removed. P values are for infecting organism as calculated by 




Figure 3-21. Gut gene content of Black/6 mice, as predicted by PICRUSt from 16S sequencing, 
changes in response to mycobacterial infection. 
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Black/6 16S sequencing samples colored by infection status and shaped by timepoint. A) All 
Black/6 samples. B) Black/6 samples with M. smegmatis infected mice removed. C) Black/6 
samples with early post-infection timepoints removed. D) Black/6 samples with early post-
infection samples and M. smegmatis infected mice removed. P values are for infecting organism 
as calculated by adonis in Vegan, and stratified by cage number. Adjusted P-value was calculated 
using FDR. 
 
Figure 3-22. Gut gene content of MyD88-/- mice, as predicted by PICRUSt from 16S sequencing, 
changes in response to M. tuberculosis infection by day 10 post-infection. 
MyD88-/- 16S sequencing samples colored by infection status and shaped by timepoint. A) All 
MyD88-/- samples. B) MyD88-/- samples with early post-infection timepoints removed. P values 
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are for infecting organism as calculated by adonis in Vegan, and stratified by cage number. 
Adjusted P-value was calculated using FDR. 
 
Figure 3-23. Gut gene content of RAG-/- mice, as predicted by PICRUSt from 16S sequencing, 
changes in response to M. tuberculosis infection. 
RAG -/- 16S sequencing samples colored by infection status and shaped by timepoint. A) All RAG -
/- samples. B) RAG -/- samples with early post-infection timepoints removed. P values are for 
infecting organism as calculated by adonis in Vegan, and stratified by cage number. Adjusted P-






Figure 3-24. Overlap between genotypes of KEGG IDs from 16S sequencing significantly 
different between M. tuberculosis infected and uninfected samples. 
Venn diagram of overlaps of significant KEGG IDs for each genotype with all timepoints (A) or 
with early timepoints removed (B). 
 
Figure 3-25. Gut gene content as predicted by HUMAnN from whole genome sequencing is 
significantly different between mouse genotypes. 
All samples from whole genome sequencing, colored by genotype and shaped by infection 





Figure 3-26. Gut gene content of Balb/c mice, as predicted by HUMAnN from whole genome 
sequencing, does not respond to mycobacterial infection. 
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Balb/c whole genome sequencing samples colored by infection status and shaped by timepoint. 
A) All Balb/c samples. B) Balb/c samples with M. avium infected mice removed. C) Balb/c 
samples with early post-infection timepoints removed. D) Balb/c samples with early post-
infection samples and M. avium infected mice removed. P values are for infecting organism as 





Figure 3-27. Gut gene content of Black/6 mice, as predicted by HUMAnN from whole genome 
sequencing, responds to mycobacterial infection. 
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Black/6 whole genome sequencing samples colored by infection status and shaped by 
timepoint. A) All Black/6 samples. B) Black/6 samples with M. smegmatis infected mice 
removed. C) Black/6 samples with early post-infection timepoints removed. D) Black/6 samples 
with early post-infection samples and M. smegmatis infected mice removed. P values are for 
infecting organism as calculated by adonis in Vegan, and stratified by cage number. Adjusted P-
value was calculated using FDR. 
 
Figure 3-28. Gut gene content of MyD88-/- mice, as predicted by HUMAnN from whole genome 
sequencing, does not respond to M. tuberculosis infection. 
MyD88-/- whole genome sequencing samples colored by infection status and shaped by 
timepoint. A) All MyD88-/- samples. B) MyD88-/- samples with early post-infection timepoints 
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removed. P values are for infecting organism as calculated by adonis in Vegan, and stratified by 
cage number. Adjusted P-value was calculated using FDR. 
 
Figure 3-29. Gut gene content of RAG-/- mice, as predicted by HUMAnN from whole genome 
sequencing, does not respond to M. tuberculosis infection. 
RAG -/- whole genome sequencing samples colored by infection status and shaped by timepoint. 
A) All RAG-/- samples. B) RAG-/- samples with early post-infection timepoints removed. P values 
are for infecting organism as calculated by adonis in Vegan, and stratified by cage number. 






Figure 3-30. Overlap between genotypes of KEGG IDs from whole genome sequencing 
significantly different between M. tuberculosis infected and uninfected samples. 
Venn diagram of overlaps of significant KEGG IDs for each genotype with all timepoints (A) or 
with early timepoints removed (B). 
 
Figure 3-31. Changes in gut microbiota gene expression with mycobacterial infection. 
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The overlap between KEGG orthologs significantly changed in expression in at least one 




Figure 3-32. Black/6 M. smegmatis-infected samples are not different in OTU composition 
from uninfected samples. 
Comparison of uninfected and M. smegmatis-infected Black/6 samples. NMDS plots from (A,C) 
16S OTU relative abundances from QIIME and (B,D) whole genome sequencing (WGS) OTU 
relative abundances from MetaPhlAn. A and B include all timepoints while C and D have the 
early post-infection timepoints removed. P values are for infecting organism as calculated by 




Figure 3-33. Black/6 M. smegmatis-infected samples are not different in functional content 
from uninfected samples. 
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Comparison of uninfected and M. smegmatis-infected Black/6 samples. NMDS plots from (A,C) 
16S functional content from PICRUSt and (B,D) whole genome sequencing (WGS) functional 
content from HUMAnN. A and B include all timepoints while C and D have the early post-
infection timepoints removed. P values are for infecting organism as calculated by adonis in 




Figure 3-34. Black/6 M. tuberculosis infected samples are significantly different from M. 
smegmatis infected samples in OTU composition. 
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Comparison of M. tuberculosis and M. smegmatis infected Black/6 samples. NMDS plots from 
(A,C) 16S OTU relative abundances from QIIME and (B,D) whole genome sequencing (WGS) OTU 
relative abundances from MetaPhlAn. A and B include all timepoints while C and D have the 
early post-infection timepoints removed. P values are for infecting organism as calculated by 




Figure 3-35. Black/6 M. tuberculosis infected samples are significantly different from M. 
smegmatis infected samples in functional content. 
Comparison of M. tuberculosis and M. smegmatis infected Black/6 samples. NMDS plots from 
(A,C) 16S functional content from PICRUSt and (B,D) whole genome sequencing (WGS) 
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functional content from HUMAnN. A and B include all timepoints while C and D have the early 
post-infection timepoints removed. P values are for infecting organism as calculated by adonis in 




Figure 3-36. Comparison of OTU composition of Balb/c M. avium infected samples and 
uninfected samples. 
Comparison of uninfected and M. avium infected Balb/c samples. NMDS plots from (A,C) 16S 
OTU relative abundances from QIIME and (B,D) whole genome sequencing (WGS) OTU relative 
abundances from MetaPhlAn. A and B include all timepoints while C and D have the early post-
infection timepoints removed. P values are for infecting organism as calculated by adonis in 








Comparison of uninfected and M. avium infected Balb/c samples. NMDS plots from (A,C) 16S 
functional content from PICRUSt and (B,D) whole genome sequencing (WGS) functional content 
from HUMAnN. A and B include all timepoints while C and D have the early post-infection 
timepoints removed. P values are for infecting organism as calculated by adonis in Vegan. 




Figure 3-38. Balb/c M. tuberculosis infected samples are significantly different from M. avium 
infected samples in OTU composition. 
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Comparison of M. tuberculosis and M. avium infected Balb/c samples. NMDS plots from (A,C) 
16S OTU relative abundances from QIIME and (B,D) whole genome sequencing (WGS) OTU 
relative abundances from MetaPhlAn. A and B include all timepoints while C and D have the 
early post-infection timepoints removed. P values are for infecting organism as calculated by 




Figure 3-39. Balb/c M. tuberculosis infected samples are significantly different from M. avium 
infected samples in functional content. 
Comparison of M. tuberculosis and M. avium infected Balb/c samples. NMDS plots from (A,C) 
16S functional content from PICRUSt and (B,D) whole genome sequencing (WGS) functional 
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content from HUMAnN. A and B include all timepoints while C and D have the early post-
infection timepoints removed. P values are for infecting organism as calculated by adonis in 
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Table 3-1. Samples collected in this experiment. 






Chapter 4: Mutation of Rv2887, a marR-like gene, confers 
Mycobacterium tuberculosis resistance to a imidazopyridine-based agent 
4.1 Abstract 
 Drug resistance is a major problem in Mycobacterium tuberculosis control, and it is 
critical to identify novel drug targets and new anti-mycobacterial compounds. We have 
previously identified an imidazo[1,2-a]pyridine-4-carbonitrile-based agent, MP-III-71, with 
strong activity against M. tuberculosis. In this study we evaluated mechanisms of resistance to 
MP-III-71. We derived three independent M. tuberculosis mutants resistant to MP-III-71 and 
conducted whole genome sequencing of these mutants. Loss of function mutations in Rv2887 
were common to all three MP-III-71-resistant mutants, and we confirmed the role of Rv2887 as 
a gene required for MP-III-71 susceptibility using complementation. The Rv2887 protein was 
previously un-annotated, but domain and homology analysis suggested it to be a transcriptional 
regulator in the MarR (multiple antibiotic resistance repressor) family, a group of proteins first 
identified in E. coli to negatively regulate efflux pumps and other mechanisms of multi-drug 
resistance. We used RNA-seq to identify genes which are differentially expressed in the 
presence and absence of a functional Rv2887 protein. One of the genes down-regulated by a 
functional Rv2887 protein is Rv2463, a putative MarA transcriptional activator. We also found 
that genes involved in benzoquinone and menaquinone biosynthesis were repressed by 
functional Rv2887. Inactivating mutations of Rv2887, a putative MarR-like transcriptional 
regulator, confer resistance to MP-III-71, an effective anti-mycobacterial compound that shows 




 Tuberculosis (TB) is a devastating disease that infects one third of the world’s 
population and killed 1.5 million people in 2013 [74]. TB is caused by Mycobacterium 
tuberculosis and is challenging and time-consuming to treat. Standard TB treatment is currently 
six months long and involves a two-month intensive phase consisting of treatment with four 
antibiotics (isoniazid, rifampin, ethambutol, and pyrazinamide) followed by a four month 
continuation phase (treatment with isoniazid and rifampin only). However, despite this 
combination therapy, drug resistance is on the rise, and in 2013, there were an estimated 
480,000 cases of multi-drug resistant tuberculosis (MDR-TB), which is defined as bacteria that 
are resistant to at least isoniazid and rifampin. These cases require up to two years of 
treatment, but even under these conditions drug resistance is developing, and in 2014, 9% of 
MDR-TB cases were extensively drug resistant (XDR), meaning that they were also resistant to 
isoniazid, rifampin, a fluoroquinolone and an injectable anti-TB drug (typically an 
aminoglycoside) [74]. Thus, there is a great need both for new antibiotics to treat M. 
tuberculosis, and for new drug targets that avoid cross-resistance to currently used therapies. 
 One such new compound is a imidazo[1,2-a]pyridine-4-carbonitrile-based agent, MP-III-
71, a compound identified by Pieroni et al. as having an MIC of 0.5 µg/mL against both drug-
susceptible and drug-resistant M. tuberculosis strains as well as a low Vero cell toxicity of >64 
µg/mL (Figure 4-1a) [75]. Thus, this compound is a promising candidate for follow up studies. 
We were particularly interested in its mechanism, since the susceptibility of MDR and XDR 




 In this study, we generated MP-III-71-resistant M. tuberculosis mutants and used whole 
genome sequencing to identify mutations associated with resistance. We found that all strains 
had loss of function mutations in Rv2887, a small nonessential gene whose only annotation was 
as a probable transcriptional regulatory protein [76]. Complementation of Rv2887 restored 
susceptibility to MP-III-71 and confirmed mutation of Rv2887 as the mechanism of resistance. 
Bioinformatics analysis suggested that Rv2887 belongs to the multiple antibiotic resistance 
repressor (MarR) family, a family of proteins originally identified in E. coli as repressing the 
expression of a transcriptional activator, MarA, which, when active, increases the expression of 
efflux pumps and porins, conferring multiple drug resistance [77,78]. Since that time, MarR 
family proteins have been found in numerous other bacterial species, functioning as both 
activators and repressors of processes such as drug efflux, virulence factors, catabolic pathways, 
and response to environmental stresses [79-83]. In addition, we conducted an RNA-seq 
transcriptome analysis of an MP-III-71 resistant strain to better understand the mechanism of 
resistance.  
4.3 Materials and Methods 
4.3.1 MP-III-71 
MP-III-71 was synthesized as previously described [75]. It was then dissolved in DMSO at 
2048 µg/mL and aliquots were stored in -80 oC until use. Synthesis of this compound and the N-
methyl derivative were performed by Dr. Marco Pieroni. 
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4.3.2 Synthesis of 2-(4-methoxybenzyl)-3,5-dimethyl-1-oxo-1,5-
dihydrobenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (the N-Me 
derivative of MP III-71) 
To a suspension of NaH (60% in mineral oil, 22 mg, 0.57 mmol) in dry DMF (2 mL), 2-(4-
methoxybenzyl)-3-methyl-1-oxo-1,5-dihydrobenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (60 
mg, 0.19 mmol), prepared as previously reported,[75] was added at 0 °C. After stirring for 15 
min, iodomethane (0.023 mL, 0.38 mmol) was added portion wise and the reaction mixture was 
refluxed for 4 h. The mixture was poured in ice-water and extracted with ethyl acetate (3 × 10 
ml), and the organic layers were washed with water and brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude material was purified through flash 
chromatography eluting with petroleum ether/ethyl acetate 90/10 to 80/20, yielding the title 
compound as a white solid. Yield: 76%. Purity: 98 %. 1H-NMR (400 MHz- d6-DMSO): δ 2.36 (s, 
3H), 3.69 (s, 3H), 3.92 (s, 2H), 4.08 (s, 3H), 6.81 (d, J = 8 Hz, 2H), 7.15 (d, J = 8 Hz, 2H), 7.41 (t, J = 
8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 1H), 8.69 (d, J = 8 Hz, 1H); 13C-NMR (100.6 MHz- 
d6-DMSO) δ 18.8, 30.8, 31.4, 55.5, 70.0, 110.2, 114.2, 116.1, 116.7, 118.0, 123.1, 127.0, 127.3, 
129.3, 132.6, 133.7, 144.8, 147.9, 158.0, 159.2. HRMS (ESI) calculated for C22H19N3O2 [M+H]
+ 
358,1477, found: 358,1482. 
The title compound was characterized through 1HNMR and 13CNMR. The 1HNMR spectra 
were recorded on a Bruker 400 Avance spectrometer (400 MHz). 13CNMR spectrum was 
recorded on a Bruker spectrometer at 100 MHz. Chemical shifts (δ scale) are reported in parts 
per million (ppm) relative to the central peak of the solvent. 1HNMR Spectra are reported in 
order: multiplicity and number of protons; signals were characterized as s (singlet), dd (doublet 
of doublet), t (triplet), m (multiplet), br s (broad signal). HRMS experiments were performed 
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using a LTQ ORBITRAP XL Thermo by Thermo-scientific instrument coupled to HPLC endowed 
with a column Alltima C18 5 µ 150mm*4.6mm, Alltech Italia Srl. Reactions were monitored by 
TLC, on Kieselgel 60 F 254 (DC-Alufolien, Merck). HPLC Method. Column: Alltima C18 5 µ 
150mm*4.6mm, Alltech Italia Srl; Flow rate = 1mL/min; isocratic elution for 5 minutes with 
CH3CN-H2O 70% with 0.2% of formic acid; gradient eluation over 25 minutes, from 95% CH3CN–
H2O with 0.2% of formic acid; isocratic elution for 10 minutes with CH3CN-H2O 95% with 0.2% of 
formic acid. 
4.3.3 Mutant isolation 
Wild-type M. tuberculosis H37Rv was grown in 7H9 broth to stationary phase 
(OD600=1.98). 500 µL was added to 7H10 plates containing 0.5, 1, 2, 4, or 8 µg/mL (2-32x MIC) of 
MP-III-71 and incubated at 37 oC for one month. Colonies grew on all plates, including three 
colonies on the 8 µg/mL plate. Each of these colonies were grown in 7H9 containing 8 µg/mL of 
MP-III-71. Of these, one colony did not grow. The other two were streaked onto 7H10 plates 
with 8 µg/mL MP-III-71 and single colonies were isolated. One colony was picked from each 
plate, and became mutant 1 and mutant 2. Mutant 3 was selected using the same method but 
from a biological repeat. In this experiment, the plate with the highest concentration of drug 
with colonies contained two colonies growing on 1 µg/mL, one large and one small. The large 
colony became mutant 3. 
4.3.4 Drug susceptibility testing 
All drug susceptibility testing was performed using the microplate alamar blue assay as 
previously described [84]. In short, bacteria were added at an OD600 of 0.001 to drug dilutions in 
7H9 without tween in a 96-well plate. Plates were incubated at 37 oC for 7 days and then alamar 
blue was added for 16 hours before plates were read using a fluorescence microplate reader at 
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544 ex/590 em. Percent inhibition was calculated based on the relative fluorescence units and 
the MIC was defined as minimum concentration that resulted in at least 90% inhibition. MP-III-
71, N-methylated MP-III-71, rifampin (Sigma), and carbonyl cyanide 3-chlorophylhydrazone 
(CCCP; Sigma) were dissolved in DMSO. Isoniazid (Fluka Analytical), ethambutol (Sigma), 
kanamycin (Sigma), verapamil hydrochloride (Sigma), chlorpromazine hydrochloride (Sigma), 
and sodium salicylate (Sigma) were dissolved in water. 
4.3.5 DNA extraction 
Extraction of genomic DNA was performed on 10 mL cultures in 7H9 broth (mutants 
were grown in 7H9 with 8 µg/mL MP-III-71) using the CTAB-lysozyme method as previously 
described [85]. 
4.3.6 Whole genome sequencing and analysis 
For samples run on the Ion Torrent Personal Genome Machine (PGM), 5 µg of genomic 
DNA were sheared using the Covaris S2 DNA system. The library was then prepared and 
enriched using the Ion Xpress Plus gDNA Kit and Ion OneTouch Template Kit on the Ion 
OneTouch, with sequencing performed using the Ion Sequencing Kit v2.0 and 316 chip (Life 
Technologies). For samples run on the SOLiD, 10 µg of genomic DNA was submitted to the Johns 
Hopkins SKCC Next Generation Sequencing Center for sequencing. Libraries were constructed 
according to the protocols provided by Life Technologies (Fragment Library kit) and were run on 
a High Sensitivity Chip using the Agilent Bioanalyzer to assess size distribution and quality of the 
amplified library.  Quantification of each library was performed by qPCR using the TaqMan Gene 
Expression Assay as outlined in the Applied Biosystems SOLiD Library Preparation Guide.  
Libraries were brought to a final concentration of 500 pM and emulsion PCR was performed to 
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generate 41,000,000 beads to deposit onto an Octet Slide.  Sequencing was performed on the 
Applied Biosystems SOLiD 3 plus System using a single read, 50 bp fragment run.  
Reads were aligned to M. tuberculosis H37Rv (GI:41353971 from GenBank) using the 
Burrows-Wheeler Alignment, and SNPs were called using the GATK toolkit [86-88]. Coverage 
analysis to identify the deletion was performed by comparing the fraction of reads in the parent 
H37Rv sequence to the fraction of reads in the mutant sequence in each 100bp window of the 
alignment and identifying the windows with > 40% difference in coverage. From these data, the 
deletion was picked out as a region with no reads in mutant 1 and an average of 53.6 reads per 
100 bp window in the Ion Torrent wild-type H37Rv sequence. 
4.3.7 Mutation confirmation 
For mutant 1, primers were designed using Primer3 to span the putative deletion [89]. 
The forward primer was 5’-GTAGCGTGCGAGGTTGAT-3’ and the reverse primer was 5’-
GAAGCGTTCTTCAGTGGAGT-3’, with an expected size of 3753bp in the parent strain and 663bp 
in the wild-type strain. In addition, primers to span Rv2887 were used for all three mutants. The 
forward primer was 5’-AATGCGATGTAGGCTTCAC-3’ and the reverse primer was 5’-
ATCCACGCCCCAAATATC-3’. Primers were synthesized by Integrated DNA Technologies and 
diluted to 10 µM in nuclease water. PCR was performed using the 25 µL Taq 2x Master Mix (New 
England Biolabs), 1 µL forward primer, 1 µL reverse primer, 1 µL genomic DNA, and 22 µL 
nuclease-free water. The PCR program was 95 oC for 3 minutes, followed by 30 cycles of 95 oC 
for 30 seconds, 53 oC for 30 seconds, and 1 minute at 68 oC. After this was 7 minutes at 68 oC 
and then products were held at 4oC.  PCR products were run on a 1% agarose gel with a 1kb Plus 
Ladder (Life Technologies), and then the bands were purified using the QIAquick gel extraction 
kit (QIAGEN). The purified product was diluted to 1.75 ng/µL and submitted with the forward 
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and reverse primers to Genewiz for Sanger sequences. BLAST was used to align the resulting 
sequences against Rv2887 to confirm the presence of the mutation [90]. 
4.3.8 Complementation 
Primers were designed using Primer3 to include all of Rv2887 and 500 bp upstream of 
the start of Rv2887 [89]. The forward primer was 5’-GGTATAGGTACCGGTCACGCCTACCACTTG-3’, 
which included a cut site for KpnI, and the reverse primer was 5’-
ATCCTCTCTAGATGATGCTCTCGGCTGATAC-3’, which included a cut site for XbaI, with an 
expected size of 1089bp. The primers were dissolved in nuclease-free water and diluted to 10 
µM. PCR was performed using 1 µL of each primer, 1500 ng of genomic DNA from M. 
tuberculosis H37Rv, 25 µL Taq 2x Master Mix (New England Biolabs), and nuclease-free water to 
bring the volume to 50 µL. The resulting mix was thermocycled at 95 oC for 3 minutes, followed 
by 30 rounds of 95 oC for 30 seconds, 58 oC for 30 seconds, and 60  oC for 2 minutes. This was 
finished with 7 minutes at 68 oC. The resulting product was purified using the QIAquick PCR 
purification kit (QIAGEN). 
 Restriction digest was performed on 2 µg of the pMH94h plasmid and 2 µg of the 
purified PCR product [91]. The digest consisted of 0.2 µL KpnI-HF (New England Biolabs), 0.2 µL 
XbaI (New England Biolabs), 5 µL NEB buffer 4, and 44.6 µL DNA and nuclease-free water. The 
mix was incubated at 37 oC for 4 hours. The digested DNA was run on 1% agarose gel and the 
bands extracted using the QIAquick gel extraction kit (QIAGEN). The digested plasmid was then 
treated with alkaline phosphatase, calf intestinal (CIP) (New England Biolabs). 50 ng of CIP-
treated digested plasmid was ligated with 150 ng of digested PCR product using the Quick 
Ligation Kit from New England Biolabs. The ligated product was used to transform E. coli One 
Shot TOP10 electrocompetent cells (Life Technologies), and the transformed bacteria were 
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plated on LB agar containing 150 µg/mL Hygromycin B (Roche). Plates were incubated overnight 
at 37 oC and four single colonies were picked the next day and grown in 5 mL LB broth with 150 
µg/mL Hygromycin B. The next day, plasmid was isolated using the QIAprep spin miniprep kit 
(QIAGEN). 
 To confirm plasmid sequence, 600 ng of purified plasmid were digested as described 
above, and the digest run on 1% agarose to confirm presence of the insert.  All four products 
were submitted to Genewiz for Sanger sequencing, along with the forward primer 5’- 
AGCGCATAGGAACGATTTAC-3’ and the reverse primer 5’- ACCCGGTAGAGCAGATAGC-3’. BLAST 
was used to confirm the correct sequence in all four plasmids; one was chosen randomly to 
continue [90]. 
 Each strain was grown to around OD600 0.8 in 50 mL of 7H9 and made electrocompetent. 
In brief, the culture was spun down for 10 minutes at 37 oC at 4500 RPM and was re-suspended 
in 30 mL of 10% glycerol (Sigma). This was repeated 4 times, halving the volume used for re-
suspension each time, until the bacterial were finally re-suspended in 2.5 mL 10% glycerol. 100 
µL of cells were incubated at 55 oC for 5 minutes and then the bacteria were electroporated 
with 25 ng/µL plasmid in 50 µL water using 330 µF / 375 Volts / 8 KOhms. The cells were then 
transferred into 2 mL of 7H9 and incubated at 37 oC for 48 hours. The transformed cells were 
then centrifuged at 10,000 RPM for 5 minutes, re-suspended in 200 µL and the entire volume 
plated on 7H11 with 50 µg/mL Hygromycin B. Plates were incubated 37 oC for four weeks. 
4.3.9 Transposon mutants 




4.3.10 RNA extraction 
Total RNA was extracted from 50 mL of culture at around 1 OD600. M. tuberculosis 
cultures were centrifuged and the bacterial pellet was resuspended in TRIzol (Invitrogen). This 
mixture was transferred to 1.8 mL O-ring tubes containing 0.5 mL of 0.1 mm glass beads 
(BioSpec Products). Cells were incubated at 25 oC for 10 minutes, lysed by six cycles of bead-
beating for 30 seconds and cooling on ice for 1 minute, using a mini-beadbeater at 4,800 RPM. 
Lysed cells were centrifuged for 5 minutes at 13,000 RPM, the supernatant was transferred to a 
fresh microfuge tube and RNA was then extracted as described [92,93]. The quality of RNA was 
assessed using a Nanodrop (ND-1000, Labtech) and Agilent 2100 Bioanalyzer (Agilent 
Technologies). 
4.3.11 Quantitative reverse-transcription PCR 
15 µg of RNA was treated with DNase I (New England Biolabs) according to 
manufacturer’s instructions. Reverse transcription was performed using the iScript Reverse 
Transcriptase (BioRad) on 1 µL of DNase-treated RNA. The primers used for Rv2887 for qRT-PCR 
were 5’-GTTCGCTACCGGCTACATTG-3’ (forward) and 5’-CTAGTCGGACCCGAGCTTCT-3’ (reverse). 
The primers for our control housekeeping gene, sigA, were 5’-CCATCCCGAAAAGGAAGACC-3’ 
(forward) and 5’- TCGAGGTCTGGTTCAGCGTC-3’ (reverse). sigA is a housekeeping gene whose 
expression remains constant and is commonly used for M. tuberculosis [94]. qRT-PCR was 
performed on 2 µL cDNA using the iQ SYBR Green Supermix (BioRad) on the Applied Biosystems 
StepOnePlus using 95 oC for 3 minutes, followed by 40 cycles of 95 oC for 15 seconds and 53 oC 
for 1 minute, then a melt curve from 55-95 oC. The average fold change compared to wild-type, 




4.3.12 Bioinformatics analysis  
BLAST alignment was performed using the online tool [90]. Consensus sequences for 
marR and marA were downloaded from the conserved domain database [95]. Secondary 
structures were predicted using the default settings for the online versions of Phyre2, 
PROMALS3D, and PRALINE [96,97]. All tools made the same prediction, and the results from 
Phyre2 are shown in Figure 4-4. Several alignment tools were used, including PRALINE, MUSCLE, 
and ClustalW, all on the default settings [98-100]. The alignment from PRALINE is the one 
depicted in Figure 4-4. The MarR protein sequences to align were selected from CDD, using the 
top five most diverse members, including the consensus sequence [95]. The GI numbers for 
these sequences were 192988597 (Salmonella typhimurium SlyA), 75341253 (Enterococcus hirae 
NapB), 81637589 (Bacillus subtilis YvnA), and 81703996 (Bacillus subtilis YhjH). The online tool 
for SIFT was used to assess the effect of non-synonymous mutations [101]. 
4.3.13 RNA-seq and analysis  
The strains were grown to an OD600 of 0.6 in 150 mL, and MP-III-71 or an equivalent 
volume of DMSO was added at to a final concentration of 0.0625 µg/mL MP-III-71. Cultures 
were incubated shaking at 37 oC for 6 hours and then RNA extraction was performed as 
described above. Ribosomal RNA was removed using the Ambion MICROBExpress Bacterial 
mRNA Enrichment Kit (Life Tehcnologies) and the results checked using the Agilent 2100 
Bioanalyzer (Agilent Technologies). Library preparation was performed using the Ion Total RNA-
Seq Kit v2 (Life Technologies). Samples were barcoded using the Ion Xpress RNA barcodes and 
each replicate was pooled into one library. Template preparation was performed with the Ion 
PGM Template OT2 200 Kit using the Ion OneTouch 2 and Ion OneTouch ES (Life Technologies). 
Sequencing was performed on the Ion Personal Genome Machine using the Ion 318 chip with 
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the Ion PGM Sequencing 300 Kit with weighted buckets (Life Technologies). Reads were aligned 
to M. tuberculosis H37Rv (GI:41353971 from GenBank) using the Burrows-Wheeler Alignment 
[87]. Differential expression was assessed using DESeq, EdsgeR and Cufflinks, all of which gave 
the same results [102-104]. Results from DE-Seq are presented here. 
4.3.14 Nucleotide accession numbers 
All sequencing data has been deposited in the GenBank Sequence Read Archive under 
BioProject PRJNA280011. Individual accession numbers are given in Table 4-1. 
4.4 Results 
4.3.1 Whole genome sequencing reveals that Rv2887 mutations confer 
MP-III-71 resistance 
 Spontaneous mutants resistant to MP-III-71 were selected by growing M. tuberculosis 
H37Rv on 7H9 agar plates containing up to 8 µg/mL of the compound, a concentration which is 
32x the MIC (see Materials and Methods). A total of three mutant colonies were identified 
during two separate selections, and their resistance to MP-III-71 was confirmed using microplate 
alamar blue assay (MABA), as shown in Table 4-2. Each mutant had an MIC of 1-2 µg/mL, which 
is 2-8x the MIC of the parent strain, which showed an MIC of 0.25-0.5 µg/mL. 
Genomic DNA from each of the three mutants and the wild-type parent H37Rv strain 
was submitted for deep sequencing. Mutant 1 and 2 and wild-type H37Rv were sequenced on 
an Ion Torrent Personal Genome Machine (PGM), with an average of 1.4 million reads and an 
average read length of 111 base-pairs (bp; Table 4-1). The parent H37Rv strain was re-
sequenced using an ABI SOLiD instrument, along with mutant 3, with an average of 25.2 million 
50 bp reads (Table 4-1). Reads were aligned to the M. tuberculosis H37Rv reference genome, 
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and mutations identified in either of the two parental H37Rv sequences were removed from 
further analysis. After this analysis, mutant 1 had 7 SNPs and 11 indels, mutant 2 had 9 SNPs and 
4 indels, and mutant 3 had 1 SNP (Table 4-3). Using the TARGET collection of mutants, we tested 
the MP-III-71 susceptibility of M. tuberculosis CDC1551 strains with a transposon inserted in 
Rv2658c or Rv3668c, the only two genes mutated in our study that had an available transposon 
mutant [105]. However, neither of these mutants had an altered susceptibility to MP-III-71 
(Table 4-4). 
Interestingly, Rv2887 was mutated in both mutant 2 and 3, with a 2 bp deletion in 
mutant 2 and a non-synonymous mutation in mutant 3, both of which were confirmed with 
Sanger sequencing of PCR amplified DNA fragments (Table 4-2). In addition, we analyzed the 
coverage of each strain, and found a 3,183 bp deletion in mutant 1, which includes Rv2887 
(Table 4-2, Figure 4-2a). The deletion was confirmed by PCR with primers inside and outside the 
deleted area (Figure 4-2b), and the outside PCR product was submitted for Sanger sequencing to 
identify the exact boundaries of the deletion. From this, we determined that the deletion was 
from position 3,194,362 to position 3,197,545 in the H37Rv reference nucleotide sequence, 
resulting in partial deletion of Rv2885c and Rv2888c, and full deletion of Rv2886c and Rv2887. 
Thus, we hypothesized that loss of function of Rv2887 confers resistance to MP-III-71. 
4.3.2 Complementation of Rv2887 confirms that mutation of this gene 
confers resistance to MP-III-71 
 Wild-type Rv2887 was cloned into an integrating pMH94-derived plasmid, along with 
500 bp upstream to capture its native promoter [91]. The plasmid was introduced into each of 
the three mutants and MABA was performed with MP-III-71. In addition, in mutant 1, which had 
a full deletion of Rv2887, real-time PCR was performed to confirm that expression of Rv2887 
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from the plasmid is the same as wild-type levels (Figure 4-3). Introduction of the wild-type 
version of Rv2887 was sufficient to restore susceptibility to MP-III-71 to wild-type levels in all 
three mutants (Table 4-2), confirming that loss of function of Rv2887 results in resistance to MP-
III-71. 
4.3.3 Comparative analysis of Rv2887 with known MarR transcriptional 
regulators 
 BLAST analysis revealed that Rv2887 belongs to the MarR Pfam family, Pfam01047, with 
an E-value of 6.38x10-13 [90,106,107]. MarR homologs contain a winged helix-turn-helix motif, 
and they have been shown to play a role either as transcriptional repressors or activators of 
several different pathways, including response to antibiotic and oxidative stress [108,109]. The 
E. coli mar (multiple antibiotic resistance) locus, which has been well characterized, consists of 
two transcriptional units, marC and marRAB, which are under the control of a centrally located 
promoter region between these two divergent operons. MarR, which has been shown to 
function as a repressor in E. coli, binds to repeats within the operator and prevents transcription 
until bound by certain chemical compounds, such as tetracycline, chloramphenicol, and sodium 
salicylate [110]. Binding induces a conformational change in MarR, which reduces its affinity for 
the repressor DNA sequence, allowing transcription of marC and marRAB. MarA, which 
functions as a transcriptional activator in E. coli, is then expressed, leading to elevated 
transcription of a diverse regulon of genes [110]. In E. coli, this regulon governs numerous 
functions including up-regulation of efflux pumps and is associated with the multiple antibiotic 
resistance phenotype. 
 Alignment of Rv2887 and the mutant strains against the consensus Pfam01047 
sequence and other members of this family showed that valine 61, mutated to alanine in 
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mutant 3, is a conserved amino acid in MarR-like proteins in multiple species, and thus this small 
amino acid change may have a significant impact on protein function (Figure 4-4) [95]. Several 
alignment tools were used, including PRALINE, MUSCLE, and ClustalW to confirm this finding; 
Figure 4-4 shows the results from PRALINE [98-100]. The importance of this amino acid was 
confirmed by SIFT, which predicted that the V61A mutation will affect protein function, based 
on the conservation of amino acid residues [101]. In addition, the 2 bp deletion in mutant 2 
changes the four C-terminal residues into 29 residues, increasing the length of the protein, and 
adding an additional disordered region including two new alpha helices (Figure 4-4c). Thus, the 
changes in both mutant 2 and mutant 3 are predicted to affect Rv2887 function. 
4.3.4 Efflux inhibitors and resistance to MP-III-71 
 Based on the role of MarR in regulating efflux pumps in E. coli, we tested the efflux 
pump inhibitors verapamil, chlorpromazine, and carbonyl cyanide 3-chlorophenyl hydrazone 
(CCCP) [111-114]. However, these compounds had no effect on the MIC of MP-III-71 to wild-
type H37Rv, mutant 1 or complemented mutant 1 (Table 4-5). Furthermore, there was no 
difference in the susceptibility of mutant 1 compared to wild-type for these three compounds. 
Thus, while Rv2887 may play a role in drug efflux in M. tuberculosis, it appears that it does not 
govern efflux pumps targeted by these three inhibitors. M. tuberculosis H37Rv has an estimated 
148 efflux pumps, and so efflux of MP-III-71 may still be controlled by loss of Rv2887 function, 
despite the lack of activity of verapamil, chlorpromazine and CCCP [115]. 
Given the role of MarR in drug resistance in E. coli and other organisms, we also tested 
whether any of the mutants had altered susceptibility to the TB antibiotics isoniazid, rifampin, 
ethambutol and kanamycin. None of the mutants showed MIC changes to these drugs compared 
to wild-type (Table 4-5; data not shown for mutants 2 and 3). This correlates with our previous 
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findings that MP-III-71 is effective against drug resistant clinical isolates, and inhibits a unique 
pathway not targeted by existing anti-TB drugs. 
4.3.5 Transcriptional profiling of an MP-III-71 resistant mutant  
 Since Rv2887 is a putative transcriptional regulator, we performed RNA-seq on the Ion 
Torrent PGM to determine whether it governs the transcription of other genes. We chose to 
focus on mutant 1 and complemented mutant 1 because mutant 1 had the full deletion of 
Rv2887, and because it had the highest MP-III-71 MIC. We harvested the RNA after 6 hours 
incubation with 0.0625 µg/mL MP-III-71 (1/4 wild-type MIC) or with an equivalent volume of 
DMSO only. Triplicate samples were run on the Ion Torrent PGM, with an average of 1.2 million 
reads and 115 bp read length (Table 4-1).  
 After performing differential expression analysis comparing the mutant and its 
complemented strain, we identified six genes that were significantly differentially expressed 
between mutant and wild-type, including Rv2887 (Table 4-6). All genes identified as significant 
were up-regulated in the MP-III-71 resistant mutant compared to the complemented strain, 
with the exception of Rv2887 and Rv2886c. Rv2886c down-regulation in the mutant is probably 
due to artifactual overexpression of this gene in the comparator strain, since the end of this 
gene is at the start of Rv2887, and the complementation plasmid contained 500 bp upstream of 
Rv2887. The fact that the other genes are up-regulated with the deletion of Rv2887 is consistent 
with the hypothesis that Rv2887 serves as a transcriptional repressor. 
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4.3.6 The regulon of Rv2887 includes genes involved in menaquinone 
biosynthesis and a potential MarA protein 
 Three of the significant genes identified in our RNA-seq analysis as being up-regulated 
upon Rv2887 deletion were Rv0560c, Rv0559c, and Rv0558. These three genes form a  cluster in 
the H37Rv genome, although Rv0558 is in the opposite orientation to the other two genes, and 
many of the reads aligned to this gene were in the other orientation, suggesting read-through 
from Rv0559c. Rv0559c encodes a non-essential exported protein found in culture filtrate, 
membrane and whole cell lysate, and, along with Rv0560c, is up-regulated in rifampin-resistant 
strains and induced by salicylate [76,116-119]. Rv0560c is a benzoquinone methyltransferase 
involved in the biosynthesis of isoprenoid compounds, and it is also up-regulated in iron-limited 
and anaerobic conditions [76,120-122]. Rv0558 (menH) encodes an S-adenosylmethionine-
dependent methyltransferase found in the membrane that catalyzes the final step in 
menaquinone biosynthesis [76,123,124]. Menaquinone (vitamin K) is an essential electron 
carrier in the respiratory chain and is particularly important in M. tuberculosis survival under low 
oxygen conditions [124]. The other gene up-regulated by Rv2887 deletions was Rv2463. This 
gene has been annotated as lipP, a probable esterase/lipase [76]. LipP has a low level of long-
chain triacylglycerol hydrolase activity, and is induced after 6 hours of nutrient starvation [125]. 
Given that Rv2887 is in the MarR family but M. tuberculosis lacks the adjacent marRAB 
locus identified in E. coli, we used BLAST to seek E. coli MarA (accession number EDV65186.1) 
homologs which may be situated elsewhere in the H37Rv genome [90]. Only 6 genes were 
identified, one of which was Rv2463, with an Expect (E) value of 0.23 (Table 4-7). Although a 
function for Rv2463 as a MarA-like transcriptional activator seems unlikely for a protein with 
lipase activity, especially given the relatively high E value, we used this same method to look for 
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other MarR-like proteins in H37Rv, with E. coli MarR (accession number AAK21292.1) as the 
query, and picked up Rv2887, in addition to 7 other potential MarR-like proteins (Table 4-7). 
Thus, M. tuberculosis H37Rv possesses several putative MarR- and MarA-like proteins. However, 
further studies will be needed to assess function. 
4.3.7 Rv2887-dependent susceptibility to MP-III-71 may involve drug 
methylation 
We hypothesized that mutation of Rv2887 may be indirectly causing resistance to MP-
III-71 by altering expression of its true target. We had access to transposon mutants of Rv0559c 
and Rv2463 [105]. Given that loss of Rv2887 caused these genes to be up-regulated, we 
hypothesized that deletion of these genes might result in MP-III-71 hyper-susceptibility. We 
tested the MIC of MP-III-71 of the Rv0559c and Rv2463 mutants. However, neither of these 
mutants had an altered susceptibility to MP-III-71, suggesting that their up-regulation with loss 
of Rv2887 is not the cause of MP-III-71 resistance (Table 4-4). However, the transposon in 
Rv2463 was inserted 2 amino acids from the C terminus, so this mutant may retain some degree 
of intact function (Table 4-4).  
This left altered expression of Rv0558 and Rv0560c as potential reasons for MP-III-71 
resistance. Rv0560c is up-regulated in the presence of salicylate, which is of particular interest 
since salicylate is one of the compounds that interferes with the repressor activity of MarR in E. 
coli [126-128]. As a result, we tested the susceptibility of mutant 1 to salicylate, but found that 
deletion of Rv2887 had no effect on the MIC of salicylate (all strains had an MIC of 250-500 
µg/mL). Sub-MIC levels of salicylate did reduce susceptibility of the mutant, but not the 
complemented or wild-type strains, to MP-III-71 (Table 4-5).  
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Since Rv0558 and Rv0560c are methylases, we next hypothesized that MP-III-71 may be 
methylated, leading to inactivation of the compound. Up-regulation of these genes by altering 
Rv2887 function would increase the amount of methylated, inactivated drug. We tested our 
strains for susceptibility to N-methylated MP-III-71 (Figure 4-1b). Interestingly, this compound 
had no effect on the growth of any strain, even at the highest concentrations tested (32 µg/mL; 
Table 4-5). This showed that methylation results in inactivation of MP-III-71 and suggests that 
one possible mechanism of resistance to this compound may be through methylation of the 
drug. 
4.4 Discussion 
 The development of new drug targets and new drugs to combat M. tuberculosis is 
critical as rates of drug resistance increase. Here, we explore the function of one potential new 
anti-mycobacterial compound, MP-III-71, and we show that loss of function mutations in Rv2887 
confer resistance to this compound.  
 Rv2887 is a transcriptional regulator in the MarR family. Very little is known about the 
role of the mar operon in mycobacteria. McDermott et al. showed that expression of E. coli 
MarA in M. smegmatis increases resistance to several antibiotics, including rifampin, isoniazid, 
ethambutol, tetracycline and chloramphenicol, suggesting that a mar-like system is present in 
mycobacteria [129]. Following this, Zhang et al. showed that in M. smegmatis, Ms6508 is a 
MarR-like protein whose corresponding marRAB operon confers rifampin resistance [130]. 
However, both of these studies were performed in the nonpathogenic organism M. smegmatis. 
To our knowledge, only one other study has focused on the mar operon in M. tuberculosis. 
Radhakrishnan et al. showed that Rv0678 is a MarR-like regulator that controls transcription of 
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the MmpS5-MmpL5 transporter, providing direct evidence of a mar-like operon in M. 
tuberculosis [131]. 
 Despite the function of its homologs in drug resistance, loss of function mutations in 
Rv2887 do not confer resistance to rifampin or isoniazid. However, intact Rv2887 does 
negatively regulate the transcription of Rv0558, Rv0559c, Rv0560c and Rv2463. Rv2463, also 
known as lipP, is a lipase that has some homology to E. coli MarA, the activator in the mar 
system, which in E. coli is negatively regulated by MarR. While the only known function of 
Rv0559c is that it is secreted, Rv0560c methylates benzoquinone (coenzyme Q) and Rv0558 
methylates menaquinone, both of which play an important role in electron transport. Thus, 
mutation of Rv2887 may confer resistance to MP-III-71 by up-regulating expression of these two 
genes, resulting in altered cellular energy levels and transport. This may lead to methylation of 
MP-III-71, causing inactivation and resistance.  
 This study revealed that M. tuberculosis susceptibility to MP-III-71 is Rv2887-dependent. 
Rv2887 is a MarR-like protein which inhibits the expression of at least six genes, including 
Rv0558, a menaquinone methyltransferase, and Rv0590c, a benzoquinone methyltransferase. A 
methylated derivative of MP-III-71 is inactive. This suggests that loss of Rv2887 leading to 




4.5 Figures  
 
Figure 4-1. Novel compounds used in this study.  





Figure 4-2. 3,183 bp deletion in mutant 1, which includes Rv2887.  
(A) Coverage analysis of sequencing results for M. tuberculosis H37Rv and mutant 1, showing 
lack of reads in this region for the mutant but not the parent H37Rv strain. (B) Confirmation of 
the deletion mutation. Lane 0 is the Invitrogen 1kb Plus DNA Ladder. Numbers over the bars 
indicate the size in base-pairs of the ladder. Lane 1 is a PCR of genomic DNA from the parent 
H37Rv strain with primers outside the region of the deletion. Lane 2 is a PCR of genomic DNA 
from mutant 1 with the same primers as lane 1. Lane 3 is a PCR of genomic DNA from H37Rv 
with primers inside the deletion (in Rv2887). Lane 4 is a PCR of mutant 1 genomic DNA with the 




Figure 4-3. Expression of Rv2887.  
Quantitative reverse transcription PCR of Rv2887, normalized to sigA. This shows Rv2887 





Figure 4-4. Rv2887 is in the MarR family.  
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(A) Alignment of Rv2887 to the consensus sequence for Pfam01047 (MarR) and four other MarR 
family proteins (selected as the five most diverse members in the conserved domain database, 
including the consensus sequence) [95]. The bottom row is the consistency, as estimated by 
PRALINE [98]. (B) Secondary structure prediction from Phyre2 for Rv2887[97]. (C) Secondary 
structure prediction for the C terminus of mutant 3. The black boxes in A and B indicate the V61, 

























1118469 118 23.90x WGS 
 
mutant 1 SRS891424 
Ion Torrent 
PGM 
1128556 113 20.30x WGS 
 
mutant 2 SRS891455 
Ion Torrent 
PGM 
2085715 101 33.90x WGS 
 H37Rv SRS891666 SOLiD 25731984 50 266.14x WGS 
  mutant 3 SRS893802 SOLiD 24748378 50 264.32x WGS 








































































































































Table 4-1. Next generation sequencing metrics.  
Statistics from all sequencing runs. WGS = whole genome sequencing. 
 









H37Rv 0.25-0.5   SOLiD and 
PGM 
  
Mutant 1 2 0.25-0.5 PGM Deletion from 3194362-3197545 (3183 bp), 
which includes Rv2885c, Rv2886c, Rv2887, 
and Rv2888c  
Mutant 2 1-2 0.25-0.5 PGM 2bp deletion at 3196830-1, which is 
nucleotide 399 in Rv2887 (amino acid 133) 
Mutant 3 1 0.25-0.5 SOLiD V61A non-synomous SNP in Rv2887 
 
















342542 A G Rv0282 D138G 
mutant 1 and 
mutant 2 
666418 G A Rv0573c L275L 
mutant 1 and 
mutant 2 
2170598 C T Rv1918c V5V 
mutant 1 and 
mutant 2 
2654064 A G Rv2374c X344R 
mutant 1 and 
mutant 2 
3894771 A G Rv3478 T116A 
mutant 1 and 
mutant 2 
3894773 C T Rv3478 T116T 
mutant 1 and 
mutant 2 
4374865 C A Rv3892c V273V 
mutant 1 and 
mutant 2 
2979619 A G Rv2658c W24R mutant 2 
4110523 C T Rv3668c intergenic mutant 2 













55533 TGCC T Rv0050 CDS 
mutant 1 and 
mutant 2 
131174 T TG Rv0108c Intergenic 
mutant 1 and 
mutant 2 
234496 C CGT Rv0197 CDS 
mutant 1 and 
mutant 2 
424320 T TC Rv0354c CDS 
mutant 1 and 
mutant 2 
1274805 CG C Rv1146 Intergenic mutant 1 
1780586 C CG Rv1575 CDS mutant 1 
3580636 CT C Rv3203 Intergenic mutant 1 
3590686 G GC Rv3213c Intergenic mutant 1 
3635239 GC G Rv3255c CDS mutant 1 




A Rv3785 CDS mutant 1 
3196829 GGA G Rv2887 intergenic mutant 2 
 













Reason tested MIC MP-III-71 
CDC1551 NA 
   
0.125-0.25 ug/mL 
JHU2658c-26 Rv2658c 369 26 
Mutated in mutant 
sequence 
0.125 ug/mL 
JHU2658c-30 Rv2658c 369 30 
Mutated in mutant 
sequence 
0.125 ug/mL 
JHU3668c-441 Rv3668c 699 441 
Mutated in mutant 
sequence 
0.25-0.125 ug/mL 
JHU0559c-124 Rv0559c 339 124 RNA-seq hit 0.25 ug/mL 
JHU0559c-202 Rv0559c 339 202 RNA-seq hit 0.25 ug/mL 
JHU2463-1183 Rv2463 1185 1183 RNA-seq hit 0.25 ug/mL 
 
Table 4-4. MIC of MP-III-71 against select transposon mutants.  
MICs are given in µg/mL. 
Drug H37Rv mutant 1 mutant 1 complement 
MP-III-71 0.125-0.5 1-2 0.125-0.5 
Me-MP-III-71 >32 >32 >32 
Isoniazid 0.04 0.04 0.04 
Rifampin 0.125 0.125 0.125 
Ethambutol 1-2 1-2 1-2 
Kanamycin 2 2 2 
Verapamil 200 200 200 
MP-III-71 + 50 ug/mL Verapamil 0.0625 1 0.3125 
Chlorpromazine 10 10 10 
Salicylate 250-500 250-500 250-500 
MP-III-71 + 62.5 ug/mL Salicylate 0.125 0.25 0.125 
CCCP 8 8 8 
MP-III-71 + 1 ug/mL CCCP 0.0625-0.5 0.5 0.125-0.5 
 
Table 4-5. MIC of select compounds against H37Rv, mutant 1 and mutant 1 complement.  




  mutant 1 + MP-III-71 vs. 
complement + MP-III-71 
mutant 1 + DMSO vs. 











Rv0560c -7.67 6.98E-58 0.00 3.29E-53 Possible benzoquinone 
methyltransferase 
(methylase) 
Rv2887 7.16 4.38E-20 75.40 1.38E-12  




Rv0559c -3.63 4.70E-11 0.05 3.38E-13 Possible conserved 
secreted protein 
Rv2463 -1.59 0.01 0.35 0.02 lipP: Probable 
esterase/lipase 
Rv2886c 2.34 0.03 3.28 1.00 Probable resolvase 
 
























































y Rv1404 34.67 75 49 0 37 111 42 116 4.00E-07 47.4 
Rv0880 27.27 110 69 2 4 113 9 107 3.00E-05 41.2 
Rv2887 25.38 130 96 1 13 142 8 136 2.00E-04 38.1 
Rv0737 27.16 81 57 1 33 111 49 129 3.00E-04 37.7 
Rv0042c 32.39 71 48 0 37 107 82 152 0.027 31.2 
Rv2922c 33.33 45 30 0 97 141 723 767 2.4 24.6 
Rv1442 33.33 24 16 0 72 95 49 72 3.9 24.3 






















Rv1931c 30.49 82 55 2 28 108 175 255 4.00E-09 53.5 
Rv3833 26.51 83 60 1 18 100 156 237 1.00E-05 42 
Rv3736 28.92 83 56 2 27 108 246 326 0.017 31.6 
Rv2463 44.83 29 12 1 42 70 168 192 0.23 27.7 
Rv0543c 30.23 43 30 0 7 49 55 97 1.7 25 
Rv0672 25.4 63 38 4 24 86 22 75 6.2 23.1 
 
Table 4-7. Results of using BLAST to compare E. coli MarR and MarA to all H37Rv proteins.  
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Chapter 5: Whole genome sequencing of Mycobacterium africanum 
strains from Mali provides insights into the mechanisms of 
geographic restriction 
Data analysis was performed with the assistance of Dr. Abigail McGuire. 
5.1 Abstract 
 Mycobacterium africanum, made up of lineages 5 and 6 within the Mycobacterium 
tuberculosis complex (MTC), causes up to half of all tuberculosis cases in West Africa, but is 
rarely found outside of this region. The reasons for this geographical restriction remain 
unknown. Possible reasons include a geographically restricted animal reservoir, a unique 
preference for hosts of West African ethnicity, and an inability to compete with other lineages 
outside of West Africa. These latter two hypotheses could be caused by loss of fitness or altered 
interactions with the host immune system. We sequenced 92 MTC clinical isolates from Mali, 
including two lineage 5 and 24 lineage 6 strains. Our genome sequencing assembly, alignment, 
phylogeny and average nucleotide identity analyses enabled us to identify features that typify 
lineages 5 and 6 and made clear that these lineages do not constitute a distinct species within 
the MTC. We found that in Mali, lineage 6 and lineage 4 strains have similar levels of diversity 
and evolve drug resistance through similar mechanisms. In the process, we identified a novel 
streptomycin resistance mutation. In addition, we found evidence of person-to-person 
transmission of lineage 6 isolates and showed that lineage 6 is not enriched for mutations in 
virulence-associated genes, suggesting lineage 6 does not have an overall loss in virulence. This 
is the largest collection of lineage 5 and 6 whole genome sequences to date, and our assembly 
and alignment data provide valuable insights into what distinguishes them from other MTC 
lineages. These lineages do not appear to be geographically restricted due to an inability to 
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transmit between West African hosts or an overall loss of virulence. However, lineage-specific 
mutations, such as mutations in cell wall structure and secretion systems, provide alternative 
mechanisms that may lead to host specificity. 
5.2 Introduction 
Mycobacterium africanum is a member of the Mycobacterium tuberculosis complex 
(MTC) that causes up to half of all tuberculosis cases in West Africa [132]. First identified by 
Castets in 1968, it was originally characterized as having biochemical characteristics 
intermediate between Mycobacterium tuberculosis, which consists of lineages 1, 2, 3, 4, and 7 
and is the main cause of human tuberculosis, and Mycobacterium bovis, an animal-adapted 
lineage which causes bovine tuberculosis [133]. Later work divided M. africanum into two 
lineages, M. africanum West African type I and M. africanum West African type II, which became 
known as lineages 5 and 6, respectively, within the MTC [134,135]. 
Lineages 5 and 6 cause a disease similar to classically defined M. tuberculosis, although 
it has been suggested that human disease caused by these lineages may differ compared to that 
caused by lineages 1-4. For example, patients with lineage 6 disease have been reported to 
show attenuated ESAT-6 responses compared to patients with classical M. tuberculosis lineage 
disease [136,137]. In addition, in liquid culture systems it has been reported that M. africanum 
has a slower growth rate with a larger bacillary size than M. tuberculosis [138,139]. While some 
studies have found that M. africanum is less virulent than M. tuberculosis, both in animal 
models and human patients [138,140-142], others show that there is no difference [143]. 
Though these contradicting results may be due to differences in the study populations, they 
underscore how little is known about lineages 5 and 6. 
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Contributing to our overall lack of knowledge, lineages 5 and 6 are not widely 
distributed around the globe, unlike lineages 1, 2, 3 and 4 [2]. They are found almost exclusively 
in patients living in West Africa, with very few cases occurring outside of this region, mostly 
involving recent immigrants from West Africa [132]. The reason for this apparent geographic 
restriction is unknown. One hypothesis is the presence of an undiscovered animal reservoir 
endemic to West Africa, which is supported by the close relationship between lineages 5 and 6 
and the animal-adapted lineages of the MTC [144,145]. Another hypothesis is that lineages 5 
and 6 have a unique predilection for humans with genetic backgrounds common in West Africa. 
In fact, using a retrospective epidemiological study of MTC in Ghana, Asante-Poku et al. showed 
that lineage 5 is associated with the Ewe ethnic group [146]. A third hypothesis is that lineages 5 
and 6 are unable to compete with other lineages outside of West Africa, either due to loss of 
fitness or decreased transmissibility, thus explaining the limited global distribution.  
Historically, mycobacterial species were defined by biochemical assays, but, as genetic 
tools became more readily available, it is now possible to identify genomic regions that define 
MTC lineages [147]. The publication of the whole genome sequence of M. africanum 
GM041182, a single lineage 6 strain, provided valuable insights into the genetics of this lineage 
[148]. For instance, the authors identified lineage 6-specific pseudogenes, a novel region not 
present in M. tuberculosis, and single nucleotide polymorphisms (SNPs) in key genes, all of 
which may play a role in the geographic restriction of lineage 6. A later study sequenced four 
additional lineage 6 isolates and was able to confirm many of these findings, but also showed 
that not all mutations identified in M. africanum GM041182 are shared by other members of 
this lineage [139]. To our knowledge, no study has closely analyzed the genetics of lineage 5. 
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From these studies, it is clear that more sequenced isolates are needed to fully 
characterize the genetics of lineages 5 and 6 and to illuminate mechanisms that may explain its 
geographic isolation. Toward this end, we sequenced 92 clinical MTC isolates from Mali, a 
country in West Africa in which 26.2% and 1.6% of tuberculosis cases are caused by lineage 6 
and lineage 5, respectively [149] [132]. Using these and previously published data, we 
performed both alignment- and assembly-based comparative analyses to further refine our 
understanding of lineage-specific genomic features that might explain the geographic 
distribution of lineages 5 and 6. To our knowledge, this is the largest collection of lineage 6 
strains sequenced to date, and the first in depth whole genomic characterization of lineage 5.  
5.3 Materials and Methods 
5.3.1 Samples 
101 Mali strains were selected from clinical isolates collected in Bamako, Mali [149], and 
included all strains identified by spoligotyping as M. africanum, M. tuberculosis T1, or M. bovis. 
Of these strains, 92 were still viable and were submitted for whole genome sequencing. These 
92 strains will be referred to as the “Mali collection”. In addition, to improve MTC lineage 
representation, we selected additional whole genome assemblies that matched the quality of 
our assemblies. These included four finished M. bovis genomes available from GenBank (M. 
bovis AF2122/97 [150], M. bovis BCG Mexico [151], M. bovis BCG Pasteur 1173P2 [152], and M. 
bovis BCG Tokyo 172 [153]), a set of 40 M. tuberculosis strains (9 lineage 1 strains, 12 lineage 2 
strains , 7 lineage 3 strains, and 12 lineage 4 strains) from South Africa [154], the finished M. 
africanum genome from Genbank (M. africanum GM041182) [148], and M. canettii CIPT 
140010059 [155]. Combined with the Mali collection, these 137 strains will be referred to as the 
“assembly collection”. Finally, all 161 strains (122 lineage 2, two lineage 3, and 37 lineage 4) 
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from a study in China were included in the variant analysis to improve geographical and lineage 
representation [156]. The samples from the China study combined with the samples from South 
Africa and Mali (for a total of 289 strains) will be referred to as the “alignment collection”. 
Supplemental Tables 5-S1 through 5-S3 lists all strains utilized in this study. 
5.3.2 Drug susceptibility testing 
Drug resistance to isoniazid, rifampicin, ethambutol and streptomycin was tested for all 
Mali strains as previously described [149]. We confirmed those results by submitting 17 strains 
to National Jewish Health in Colorado for agar proportion testing of isoniazid, rifampicin, 
ethambutol, ofloxacin, niacin, kanamycin, ethionamide, capreomycin, amikacin, cycloserine and 
para-aminosalicylic acid, as well as radiometric testing of ciprofloxacin and pyrazinamide. The 
agar proportion results confirmed the mycobacterial growth indicator tube (MGIT) tests 
performed in Mali. Genotypic drug resistance was determined for rifampicin, isoniazid, 
ethambutol, streptomycin, ofloxacin, kanamycin and ethionamide using genetic markers from 
line-probe assays (Supplemental Table 5-S4). 
5.3.3 Genome sequencing 
Extraction of genomic DNA was performed on 10mL cultures grown in 7H9 broth using 
the CTAB-lysozyme method as previously described [85]). Library preparation and whole 
genome sequencing (WGS) were performed as previously described [157-159]. GenBank 
accessions for all strains used in this analysis can be found in Supplemental Tables 5-S1 to 5-S3, 
along with assembly statistics for the new sequences generated at the Broad Institute (92 




All genomes in our assembly collection were uniformly annotated by transferring 
annotations from M. tuberculosis H37Rv. The reference M. tuberculosis H37Rv genome 
(accession CP003248.2) was aligned to draft assemblies using Nucmer [160]. This alignment was 
used to map reference genes over to the target genomes. Using this methodology, annotations 
were successfully transferred onto all 137 strains for 3466 of the M. tuberculosis H37Rv genes; 
the rest of the M. tuberculosis H37Rv genes transferred to a subset of the genomes.  
For those genes not cleanly mapping to M. tuberculosis H37Rv, the protein-coding genes were 
predicted with the software tool Prodigal [161]. tRNAs were identified by tRNAscan-SE [162] and 
rRNA genes were predicted using RNAmmer [163]. Gene product names were assigned based on 
top blast hits against SwissProt protein database (>=70% identity and >=70% query coverage), 
and protein family profile search against the TIGRfam hmmer equivalogs. Additional annotation 
analyses performed include Pfam [164], TIGRfam [165], KEGG [166], COG [167], GO [168], EC 
[169], SignalP [170], and TMHMM [171].  
5.3.5 Orthogroup clustering and Phylogenetic trees 
SYNERGY2 [172-174], available at http://sourceforge.net/projects/synergytwo/, was 
used to identify cluster-based orthogroups across our assembly collection of 137 genomes. In 
addition, for each M. tuberculosis H37Rv gene, we defined a second set of annotation transfer-
based ortholog groups as the set of genes for which annotations were transferred from this M. 
tuberculosis H37Rv gene in our annotation protocol. Genes without M. tuberculosis H37Rv 
orthologs were manually examined in the context of their SYNERGY orthogroups to identify 
lineage-specific novel genes. 
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Phylogenetic trees were generated by applying RAxML [175] to a concatenated alignment of 
3343 single-copy core SYNERGY cluster-based orthogroups (excluding orthogroups with 
paralogs) across all 137 organisms. Bootstrapping was performed using RAxML’s rapid 
bootstrapping algorithm (1000 iterations).  
5.3.6 Average Nucleotide Identity analysis (ANI) 
Calculations of ANI were done using our assembly collection as previously described 
[176,177], using our SYNERGY cluster-based orthogroups, with a threshold for species identity 
differing by more than 5%. 
5.3.7 Gene Content Analysis 
PAUP [178] was used to reconstruct gain and loss of M. tuberculosis H37Rv orthologs at 
ancestral nodes of the assembly collection phylogenetic tree using parsimony, using our 
ortholog groups based on annotation transfer.  
In order to analyze changes in gene content, we used a cost matrix with values of 10 for 
a gene gain, 5 for a gene loss, and 0.2 for an increase or decrease in copy number. We looked 
for orthologs found within all members of one clade, and absent in other clades. As a further 
filter, we also required that orthogroups be found in >80% of the clade of interest, and <20% of 
other strains. We performed this analysis for five key clades: lineage 5, lineage 6, M. bovis, the 
clade including M. bovis and lineage 6, and the clade including lineages 5, 6 and M. bovis.  
In addition, we selected the Pfam gene categories most expanded or reduced in each clade of 
interest. We determined significance using Fisher’s test (P<0.05). For each of the clades 




5.3.8 Identification of SNPs 
 For our alignment collection, reads were mapped onto a reference strain of M. 
tuberculosis H37Rv (GenBank accession number CP003248.2) using BWA version 0.5.9.9 [87]. In 
cases where read coverage of the reference was greater than 200x, reads were down-sampled 
using Picard [179] prior to mapping. Variants, including both single nucleotide polymorphisms 
(SNPs) and multi-nucleotide polymorphisms, were identified using Pilon version 1.5 as described 
[157] and were used to construct phylogenetic trees using FastTree [180].  
We defined lineage-specific variants as those with positive predictive value >95%, 
negative predictive value >95%, true positive rate >95%, true negative rate >95%, and number 
of true positives >7. Mutations were considered M. africanum-specific (lineage 5 and 6-specific, 
identified as LIN-Maf in the tables) if they met these cutoffs for lineage 5 and 6 combined and 
were present in both lineage 5 strains. Similarly, mutations were considered M. tuberculosis-
specific if they met these cutoffs for lineages 1-4 combined. No M. tuberculosis-specific 
mutations were identified. Due to inclusion of only two lineage 5 strains in our dataset, no 
lineage-specific variants were identified in lineage 5. Thus, for this lineage only, we used a less 
stringent requirement to define lineage-specific variants: we required that variants be present in 
both lineage 5 strains and in <5% of the strains in each other lineage. We classified each gene 
containing a lineage-specific variant into functional group categories, including Gene Ontology 
(GO) [168], KEGG [166], Pfam [164], and COG [167]. We then evaluated enrichment using 
Fisher's Exact test and corrected for multiple comparisons using the Storey method for 
functional group categories [181]. 
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5.3.9 Identification of pseudogenes 
A pseudogene was defined as any gene that had a loss of function mutation anywhere 
within the coding sequence. Loss of function mutations were defined as nonsense mutations or 
insertions or deletions that were not in multiples of 3 base pairs or were greater than 30 base 
pairs. Lineage-specific pseudogenes were determined using the same definitions as for variants 
on a per gene basis (positive predictive value > 95%, negative predictive value >95%, true 
positive rate >95%, true negative rate >95%, number of true positives >7, with the exception of 
lineage 5, which used the SNP cutoffs of pseudogene in both lineage 5 strains and in >5% in each 
other lineage). 
5.3.10 Computational gene function assessments 
The effect of select non-synonymous mutations on protein function was assessed using 
the online version of SIFT at default settings [101], unless there was low confidence in the 
prediction, in which case SIFT was run for each of the four available databases (UniRef90 from 
April 2011 [default], UniProt-SwissProt 57.15 from April 2011, UniProt-TrEMBL from March 2009 
and NCBI nonredundant from March 2011). Peptide binding was predicted using the NetMHCII 
online tool with default settings [182]. 
5.4 Results 
5.4.1 M. africanum and M. tuberculosis lineages are part of the same 
species 
Our Mali collection of 92 clinical MTC strains was isolated from patients presenting with 
pulmonary tuberculosis at Point G, Bamako, Mali between 2006 and 2010 as part of a cross-
sectional study to analyze the diversity of the MTC in Mali [149]. All patients were Mali natives, 
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with the exception of one patient born in central Africa (Supplemental Table 5-S1). We 
sequenced this collection using the Illumina sequencing platform, and the resulting reads were 
both assembled into contigs and aligned against the M. tuberculosis H37Rv reference genome. 
Based on our phylogenetic reconstructions, our collection included one lineage 1, two lineage 2, 
zero lineage 3, 63 lineage 4, two lineage 5 and twenty-four lineage 6 strains (Figure 5-1). In 
order to perform statistical comparisons of the M. tuberculosis, M. africanum and M. bovis 
lineages, this dataset (the Mali collection) was combined with data from additional strains from 
GenBank and South Africa (assembly collection, Figure 5-2), as well as data from China 
(alignment collection; see Materials and Methods and Supplemental Tables 5-S1 through 5-S3). 
These additional comparator genomes enabled us to examine the distinguishing characteristics 
of lineages 5 and 6 in detail. 
Since this represents the largest collection of whole genome sequences of lineage 5 and 
6 strains to date, we used our assembly collection to conduct a detailed examination of their 
phylogeny and characteristics in relation to other members of the MTC, including M. bovis and 
M. tuberculosis. M. bovis is considered an animal strain that mainly infects cattle and rarely 
humans, while M. tuberculosis is human adapted, and lineages 5 and 6 are thought to be 
intermediate between the two [132,144]. Using our assembly collection, we constructed a high-
resolution phylogenetic tree using 3,343 single-copy core orthogroups (sets of orthologs) 
conserved across all 137 strains (Materials and Methods). This tree was rooted using the 
outgroup M. canettii and agreed with phylogenies observed by other groups, including the fact 
that each of the lineages was clearly separated from the other, with lineage 5 being more 
closely related to human-adapted strains and lineage 6 being more closely related to M. bovis, 
although all of these lineages were very closely related (Figure 5-2) [2,144].  
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It has been previously shown, using average nucleotide identity (ANI) analysis, that 
separate bacterial species share <65-90% of genes and have no more than 94-95% ANI among 
shared genes [176,177]. Using gene content and nucleotide variation among shared genes, we 
examined the genetic distances between strains within the assembly collection to understand 
how mycobacterial species fit within this framework. We observed that there was little diversity 
within the lineages analyzed. Strikingly, values from inter-lineage comparisons of M. 
tuberculosis, M. bovis, and M. africanum strains overlapped those from intra-lineage 
comparisons, showing very little separation, with >99% ANI and >94% fraction of shared genes 
(Figure 5-3) suggesting that these different organisms should not, in fact, be named different 
species.  
In contrast, MTC pairwise comparisons with M. canettii revealed a clear separation 
between the two groups suggesting that they occupy distinct niches (Figure 5-3). M. canettii is a 
smooth tubercle bacilli that causes human tuberculosis in East Africa and is considered an 
emerging pathogen in some parts of the world, but its natural host(s) and reservoirs remain 
unknown [183]. Thus, it might be argued, based on these data and the traditional cutoffs set by 
ANI analysis, that all MTC members should be named the same species, and that even M. 
canettii should be included since pairwise identities with MTC exceeded these thresholds (Figure 
5-3). However, as Smith et al. have previously discussed [184] changes in nomenclature can 
cause confusion in the literature, and so we will continue to refer to M. africanum-associated 
lineages as either lineage 5 or 6 within the MTC. 
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5.4.2 Lineage 6 is involved in recent person-to-person transmission 
events and is as diverse as lineage 4 strains in Mali 
Despite the fact that lineages 5 and 6 are so closely related to lineages 1-4, as 
demonstrated by our ANI plots, they are still unique in being geographically restricted compared 
to these other lineages. One hypothesis for this restriction is that they are less fit and thus 
unable to compete with other lineages within the MTC.  To examine this possibility, we looked 
within the Mali collection for clues that lineage 5 and 6 strains were undergoing changes in 
population structure that might suggest that these lineages are slowly dying out. Using 
alignments of our Mali collection to M. tuberculosis H37Rv, we found that the two lineage 5 
strains were not closely related. However, within lineage 6, we observed three pairs of strains 
that were separated by less than 10 SNPs (see Materials and Methods). There were six such 
clusters within lineage 4. A cutoff of 12 SNPs has previously been used to determine recent 
transmission [185]. Thus, strains separated by less than 10 SNPs provide evidence of 
transmission, suggesting that 6 of 24 (25%) of our lineage 6 strains and 13 of 63 (21%) of our 
lineage 4 strains were involved in recent transmission events, confirming previous observations 
based on alternative genotyping approaches that there is robust ongoing transmission of lineage 
6 within this region [140].  
Alignment-based approaches can miss differences in regions not present in the 
reference (in this case M. tuberculosis H37Rv, which is in lineage 4), so, to further address the 
question of whether lineage 6 is dying or succeeding, we analyzed the diversity within lineage 6 
using our assembly collection and compared this diversity to that of the predominant M. 
tuberculosis lineage in this region, lineage 4. Diversity, as measured by ANI of shared genes, was 
comparable for lineage 6 and lineage 4 strains from Mali (Figure 5-4), with no statistical 
139 
 
difference among diversity values when comparing between the two groups. Although this 
result does not eliminate the possibility of differing ecologies, such as an animal reservoir for 
lineage 6, as has previously been hypothesized [145], it does suggest that lineages 4 and 6 in 
Mali are under similar evolutionary pressures and are responding to them in a comparable 
manner.  These results also show that lineage 6 strains—which are geographically restricted--are 
adapting to evolutionary pressure by maintaining diversity comparably to lineage 4 strains from 
the region which are not geographically restricted. 
5.4.3 Lineages 5 and 6 are not enriched for mutations in genes 
associated with virulence 
Given the reports of lineages 5 and 6 strains having decreased virulence [138,140-142], 
we hypothesized that altered virulence may contribute to geographical restriction, either due to 
changes in host requirements or to a reduction in fitness. To test this hypothesis, we examined 
lineage-specific pseudogenes (truncated genes) and non-synonymous SNPs in known essential 
genes, slow growth genes, and genes required for virulence in mice and growth in macrophages 
to determine whether lineages 5 and 6 had an enrichment of defects in these genes that might 
contribute to altered virulence [186-188]. Although both lineage 5 and 6 had lineage-specific 
mutations in these gene categories (Supplemental Table 5-S5) so did other lineages, and the 
proportion of mutated genes in lineage 6 was not significantly different from that of the other 
MTC lineages [139] (Figure 5-5). Lineage 4 was not included on this graph because it only had 
one lineage-specific mutation in an intergenic region when aligned to M. tuberculosis H37Rv, 
which is a member of lineage 4, and lineage 5 was excluded due to low sample size. We 
performed a similar analysis on the full length of genes encoding known T cell antigens as 
defined by Comas et al. to explore whether alterations in these genes might be restricting host 
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specificity, but again we observed no significant difference in the proportion of lineage 6-specific 
mutations that fell within these genes as compared to lineages 1, 2 and 3 (Figure 5-5) [135]. 
Similarly, we looked for enrichment in lineage-specific mutations in COG, GO, KEGG, Pfam and 
TIGRfam gene categories, but found no enrichment in any of these categories, either for 
pseudogenes or non-synonymous SNPs. This corroborates our observations from ANI that the 
lineages of the MTC are very similar in their overall genetic composition and suggests that 
lineage 6 may not be impaired in virulence.  However, while the overall number of mutations in 
virulence genes was not enriched, we identified mutations in these genes that will be discussed 
below. 
5.4.4 Lineage 6 evolves drug resistance through similar mechanisms to 
other MTC lineages 
Studies have shown that lineages 5 and 6 evolve drug resistance less often compared to 
other MTC lineages, including the study from which these sequenced strains were obtained 
[149,189]. Thus, one hypothesis for the limited geographic range of lineages 5 and 6 could be 
decreased fitness relative to strains better able to evolve antibiotic resistance. In this case, we 
would expect that mutations driving drug resistance in these two lineages would be different 
from those evolving in more successful lineages. Thus, we analyzed the entire Mali collection for 
the presence of mutations known to confer drug resistance. The mutations are used in common 
nucleic acid-based commercial tests [190,191] for the detection of drug resistance [192-198] 
(Supplemental Table 5-S4). We compared the identified genotypic drug resistance-conferring 
mutations with our phenotypic characterization of rifampicin, isoniazid, ethambutol and 
streptomycin, and had high sensitivity and specificity for isoniazid, rifampicin, and ethambutol, 
but poor sensitivity for streptomycin (Figure 5-1 and Supplemental Figure 5-S1; Table 5-1). Forty 
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(60%) strains in lineage 1-4 and only four (15%) of the lineage 5 and 6 strains were resistant to at 
least one of these drugs. In addition, we identified known mutations in genes associated with 
resistance to drugs that were not phenotypically assessed including ofloxacin, kanamycin, and 
ethionamide. 
None of the phenotypic streptomycin resistance was explained by mutations contained 
in our list of known mutations (Figure 5-1). However, when we looked more closely at mutations 
in genes known to play a role in resistance to streptomycin, we observed that 23 of the 35 
strains with unexplained streptomycin resistance harbored a non-synonymous point mutation in 
the gidB gene (Supplemental Figure 5-S1d). While SNPs in the gidB gene have previously been 
reported in association with streptomycin resistance, this particular SNP has not heretofore 
been identified [199]. This mutation, at position 236, changes a leucine to a serine, and was 
predicted by the SIFT algorithm [101] to affect GidB protein function. Of the remaining 12 
strains with unexplained streptomycin mutation, 10 had different mutations in gidB, and 2 had 
mutations in rpsL, another gene known to have a role in resistance to streptomycin [200]. Thus, 
it appears that strains circulating in Mali might have evolved streptomycin resistance via unique 
changes in gidB. 
Using the list of mutations in Supplemental Table 5-S4, we found that 25 (38%) of the 
Mali strains belonging to lineages 1, 2 or 4 could be classified as MDR (multi-drug resistant; 
resistant to isoniazid and rifampin), and two (3%) could be classified as pre-XDR (pre-extensively 
drug resistant; resistant to isoniazid, rifampin, plus either ofloxacin or kanamycin). In contrast, 
three (11%) of the lineage 5 and 6 strains could be classified as MDR, and one (4%) could be 
classified as pre-XDR. The presence of these pre-XDR strains is of particular concern, as XDR has 
not been reported in Mali, and testing is not currently performed routinely for second line 
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antibiotics [1,201]. However, similar resistance-conferring mutations were found between the 
lineages (Supplemental Figure 5-S1).  Thus, although the sample size was small, our results 
suggest that drug resistance, while less frequent in lineage 6, evolves through acquisition of 
similar mutations to lineages 2 and 4 in Mali. 
5.4.5 Evolutionary history:  Nodes A-D 
At each node we used a combination of assembly and alignment data to identify 
distinguishing characteristics of the putative ancestral strain at that node. First, we used the 
assembly collection to identify orthologs that were either gained or lost at each node (Table 5-2; 
Materials and Methods). Many of these genes fell into already known regions of difference 
(RDs), previously identified by genome hybridizations [134,147]. For some RDs, the first and/or 
last gene in the region was not identified in our analysis because enough of the gene remained 
to align to M. tuberculosis H37Rv, and thus was not considered absent. Second, we used 
functional Pfam annotation of genes from the assembly collection to detect protein domains 
that were significantly enriched or reduced within the members of each group. Third, we used 
variant calls from our alignment collection to identify other mutations (smaller than a gene) that 
were enriched or specific to each group, including those that caused truncations of genes 
(pseudogenes) that are likely to affect protein function (Tables 5-2, Supplemental Tables 5-S5 
through 5-S8). Our alignment collection enabled us to more accurately determine what features 
were specific to a particular lineage, and showed that many mutations and pseudogenes 
previously identified as lineage-specific were not lineage-specific when evaluating our larger set 
of strains (Table 5-3 and Supplemental Table 5-S8). 
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5.4.5.1 Node A: root node of lineage 6 
The Mali collection provided a large and diverse collection of lineage 6 strains, which 
allowed us to more fully characterize the genetic content of this lineage than had been done 
previously [139,148]. We observed no gene gains at the root node of lineage 6 (Node A in Figure 
5-2), and only one gene loss (previously identified as part of RD701), as expected from earlier 
phylogenetic work (Table 5-2) [134].  
However, the traits resulting in geographic restriction of this lineage are likely due to 
smaller variants within genes or in intergenic regions altering gene expression, rather than in 
large genetic changes.  When reads from lineage 6 strains were aligned to M. tuberculosis 
H37Rv, we observed 681 lineage 6-specific mutations, 82 of which were in intergenic regions 
and the rest (599) were within coding sequences, including 8 that resulted in truncated proteins 
likely to have abolished function (pseudogenes) (Table 5-4, Supplemental Tables 5-S5 to 5-S7). 
Five of these pseudogenes had previously been identified, while three were novel (Table 5-3 and 
Supplemental Table 5-S8) [148]. Table 5-S8 provides a side-by-side perspective of the lineage 6 
pseudogenes that we detected and demonstrates that the genes identified by Bentley et al., but 
not by this study, were either pseudogenes in some other lineages, or were not pseudogenes in 
all lineage 6 strains.  
5.4.5.2 Node B: root node of lineage 6 and M. bovis 
M. africanum was first identified due to its intermediate phenotype between M. bovis 
and M. tuberculosis, which was confirmed by its genetic position on the MTC tree [133,144]. 
Based on this tree, and the tree generated by our own data, lineage 6 and M. bovis share a root 
ancestor separate from all other MTC lineages (Node B in Figure 5-2). Thus, although we did not 
have alignment data for M. bovis, we were interested in how the genetic content of these two 
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lineages compared. M. bovis and lineage 6 shared loss of RD10, RD7, and RD8 compared to 
lineage 5 (Table 5-2), corresponding with previous observations [147]. Our Pfam analysis 
revealed that these two lineages also share a copy number reduction in the MCE Pfam category 
(PF02470.15), as a result of loss of MCE operon 3, which is contained in RD7. In addition, we 
identified two genes that were gained at this node (Table 5-2). One of these genes is a PE-PGRS 
protein; the other is a hypothetical protein. 
5.4.5.3 Node C: root node of lineage 5 
To our knowledge, this is the first study to perform an in-depth analysis of the whole 
genome sequence of lineage 5 isolates. Though our dataset contained only two lineage 5 strains, 
they provided valuable insights into the specific features of this lineage. For example, our gene 
content analysis revealed the loss of RD711, RD713, and RD743 at Node C, as expected, but also 
identified two additional lineage specific genes losses that were not part of any known region of 
difference [134] (Table 5-2). One of these genes is Rv1523, which is annotated as a 
methyltransferase, and is most likely S-adenosyl-L-methionine dependent. KEGG predicts this 
gene to be in the pathways for tyrosine metabolism (ko00350) and polycyclic aromatic 
hydrocarbon degradation (ko00624). The other novel lost gene is Rv3514, annotated as PE-
PGRS57. This is part of a larger family of proteins that are highly polymorphic and may play a 
role in antigenicity. 
In addition to these larger changes, we identified 952 lineage 5-specific mutations and 
43 lineage 5- specific pseudogenes (Table 5-4, Supplemental Tables 5-S5 to 5-S7). The larger 
number of lineage-specific mutations and pseudogenes compared to the other lineages was a 
result of our small sample size, which required us to use different cutoffs. However, the average 
number of mutations per strain for lineage 5 was comparable to the other lineages in our study 
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(Table 5-4). Nevertheless, given the lack of literature on this lineage, these mutations provide 
novel insights into the distinguishing characteristics of this lineage. 
5.4.5.4 Node D: root node of lineage 5, 6 and M. bovis 
Through genomic hybridization studies, it is known that all M. bovis and M. africanum 
strains share the loss of RD9 [147]. Our gene content analysis of Node D confirmed this finding 
and identified one additional gene lost at this node and one gained gene (Table 5-2). The lost 
gene was Rv2084, which is annotated as a hypothetical protein but had BLAST similarity to a 
TetR family transcriptional regulator. The gained gene was a PPE family protein.  In addition, our 
analysis of changes in Pfam content revealed loss of two families. One of these was PF13276.1, 
which consists of proteins with a helix-turn-helix domain. The helix-turn-helix is a motif involved 
in DNA binding. This suggested a change in gene expression in these three lineages, a suggestion 
supported by the fact that the other Pfam domain lost at this node was PF12349.3, a sterol-
sensing Pfam domain. Since we did not have alignments of any M. bovis strains, we focused on 
mutations shared between lineages 5 and 6. There were 90 shared mutations, including 5 
pseudogenes (Tables 5-S5 to 5-S7).  
5.4.6 Individual lineage-specific features suggest additional mechanisms 
that could be involved in geographic restriction 
5.4.6.1 Mutations in ESX secretion systems are common in all MTC lineages 
One distinguishing clinical characteristic of lineage 6 is an attenuated T cell response to 
ESAT-6 in patients infected with this lineage as compared to patients infected with lineages 1-4 
[136]. This altered immune response supports the hypothesis that there is lineage 5 and 6 
specificity for a particular host immunogenic background. While it was hypothesized that the 
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attenuated immune response was due to mutation of Rv3879c, which is part of the ESX-1 
secretion pathway, complementation of this gene did not restore ESAT-6 secretion or 
presentation to T cells, suggesting that defective Rv3879c is not the cause of the altered 
immune response [138]. Although Bentley et al. reported that Rv3879c was a pseudogene in M. 
africanum GM041182, we found that the pseudogenization of Rv3879c was not lineage specific, 
as not all lineage 6 strains encoded truncated versions of this protein, and many strains in other 
lineages were also truncated (Supplemental Table 5-S8)[148]. This suggested that inactivation of 
Rv3879c is unlikely to explain either the host preference or the altered host immune response of 
lineages 5 and 6. In fact, Rv3879c had lineage specific mutations in lineages 1, 2 and 5, but not 
lineage 6 (Table 5-5, Supplemental Tables 5-S5, 5-S9). However, we did observe lineage 5 and 6 
specific polymorphisms in other genes involved in ESX secretion systems that might explain the 
different immune responses of lineage 6-infected patients as compared to those infected with 
other lineages (Table 5-5). Eight of the nonsynonymous mutations were predicted to affect 
protein function, but even mutations not predicted to affect protein function might also affect 
the antigenicity of these secretion systems [101]. In fact, we observed lineage specific mutations 
in ESX-encoding genes in all lineages, suggesting that each lineage may have unique interactions 
with the host (Table 5-5). Thus, our data show that ESX-secretion system polymorphisms are 
common across all MTC lineages and are not unique to lineages 5 and 6. 
5.4.6.2 Alterations in abundantly secreted proteins in lineages 5 and 6 
We also observed lineage 6 specific polymorphisms in other genes that are predicted to 
have a role in modulating the host’s immune response. For example, we identified 
nonsynonymous changes in the gene encoding antigen 85B (Rv1866), a secreted immunogenic 
protein that has been proposed as a potential vaccine target [202] (Table 5-5, Supplemental 
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Tables 5-S5 and 5-S9). No other lineages had a lineage-specific mutation in this gene. Though 
SIFT predicted that this change would not affect protein function, NetMHCII, an online tool that 
predicts binding of peptides to MHC class II alleles, predicted that that this mutation would 
change the binding of one of the putative strong binding peptides [101,182]. Although lineage 5 
did not contain lineage-specific mutations in antigen 85B, we detected a lineage 5 specific SNP 
in another abundantly secreted protein, MPT64 (Rv1980c) (Table 5-5, Supplemental Tables 5-S5 
and 5-S9). This mutation was predicted to affect both protein function and binding to MHC class 
II molecules [101,182]. Thus, part of the reason for geographical restriction of lineages 5 and 6 
may be due to alterations in the pathogen-host immune interaction. This is a particular concern 
for vaccine development in West Africa. 
5.4.6.3 Mutations in L,D transpeptidases 
It has previously been shown that M. africanum GM041182 has a distinct physiology as 
compared to of M. tuberculosis H37Rv, as M. africanum GM041182 had a larger cell size and 
slower growth rate [138]. Possibly explaining these differences, we identified lineage 6-specific 
nonsynonymous SNPs in genes encoding the L,D transpeptidases, LdtA and LdtB (Rv0166c and 
Rv2518c), shown to form cross-linkages within peptidoglycan (Table 5-5, Supplemental Tables 5-
S5 and 5-S9) [203]. When LdtA and LdtB homologs were inactivated in M. tuberculosis CDC1551 
(LdtMt1 and LdtMt2), differences in cell shape, size, surface morphology, growth and virulence 
were observed [204]. Only the SNP in LdtA was predicted to affect protein function [101]. 
Lineage 5 also contained a non-synonymous SNP predicted to affect protein function in LdtA 
(Table 5-5, Supplemental Tables 5-S5 and 5-S9). No other lineages had a lineage-specific 
mutation in an L,D-transpeptidase.  
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5.4.6.4 Loss of mammalian cell entry (MCE) proteins in lineages 5 and 6 
M. tuberculosis H37Rv contains four mammalian cell entry (MCE) operons, which play an 
important role in mycobacterial virulence [205]. Beyond the earlier report that all lineage 6 
strains lacked operon 3 as part of RD7 [147] (Table 5-2), we observed lineage 6-specific 
nonsynonymous SNPs impacting a protein from MCE operon 1 and two proteins from MCE 
operon 2, as well as a nonsynonymous mutation in the gene encoding Mce1B shared with 
lineage 5. In lineage 5 strains, the MCE operons 1 and 3 had nonsynonymous mutations. Only 
MCE operon 4 did not contain a lineage-specific mutation in either lineage, while operons 1 and 
3 were mutated in both (Table 5-5, Supplemental Tables 5-S5 and 5-S9). In M. tuberculosis 
H37Rv, each of these operons has a different expression profile in culture and, when deleted, 
they have distinct growth defect phenotypes in mice [187,206].  Thus, the presence of a wild-
type operon 4 in lineages 5 and 6 may not compensate for mutations in other operons that 
impact MCE function.  In comparison, the other lineages had nearly identical MCE operons as 
compared to M. tuberculosis H37Rv (Table 5-5, Supplemental Tables 5-S5 and 5-S9).  
5.4.6.5 Alterations in metabolism in lineages 5 and 6 
Lineage 6 had lineage-specific mutations, including pseudogenes, in multiple 
components of important biosynthetic pathways, such as molybdenum and cobalamin synthesis 
(Table 5-5, Supplemental Tables 5-S5, 5-S7 and 5-S9). Molybdenum cofactors are key catalysts 
for redox reactions, and are an important part of the evolution of pathogenic mycobacteria 
[207]. We detected lineage 6-specific nonsynonymous SNPs in two molybdopterin biosynthesis 
proteins and in the gene encoding the molybdenum transporter, ModC (Table 5-5, 
Supplemental Tables 5-S5 and 5-S9). In addition, mycobacteria are one of the few bacterial 
pathogens with the ability to synthesize vitamin B12, another important cofactor [208]. Bentley 
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et al. reported that two of the genes encoding the biosynthesis proteins, CobL and CobK, are 
pseudogenes in all lineage 5 and 6 strains [148]. We found that loss of function in cobL is specific 
to both lineage 5 and 6 but cobK, while a pseudogene in both lineages, is also a pseudogene in 
all lineage 1 strains and some lineage 2 and lineage 4 strains (Table 5-5, Supplemental Table 5-S7 
and 5-S8). We also observed a lineage 6 specific nonsynonymous SNP in cobD, although SIFT 
predicted that this change would not affect protein function [101] (Supplemental Table 5-S5). 
Loss of these cofactor biosynthetic pathways could have ramifications on the function of 
proteins that use these cofactors, and thus could have indirect effects on host-pathogen 
interactions. 
The vitamin B12 pathway was also mutated in lineage 5. Lineage 5 had a 
nonsynonymous mutation in four of the cobalamin synthesis enzymes and two flavoproteins. In 
addition, there was a nonsynonymous mutation in a riboflavin biosynthesis protein, part of the 
vitamin B3 biosynthetic pathway (Table 5-5, Supplemental Tables 5-S5 and 5-S9). The mutations 
in cobO, cobM and cobU, all important parts of the vitamin B12 pathway, were all predicted to 
affect protein function [101]. Similarly, one of the molybdenum cofactor biosynthesis genes was 
a pseudogene while another contained a nonsynonymous mutation (Table 5-5, Supplemental 
Tables 5-S5, 5-S7 and 5-S9). Besides the pseudogene in cobK in lineage 1 and some lineage 2 and 
4 strains, lineage 2 had an insertion in cobB resulting in a pseudogene, while lineage 1 had 
nonsynonymous mutations in three molybdenum-associated genes (Supplemental Table 5-S7). 
Likewise, only lineage 1 had a nonsynonmous mutation (a deletion) in a riboflavin-associated 
gene (Table 5-5, Supplemental Tables 5-S5 and 5-S9). Thus, though mutations in these genes are 
seen in other MTC lineages, lineages 5 and 6 seem to have an increased number of mutations in 
cobalamin and vitamin B biosynthesis pathways. Differences in cofactor synthesis could indicate 
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a in a lineage 5 and 6 preference for a different host environment, as in the case of an animal 
reservoir or variation in host immune pressures. 
5.4.6.6 Mutations in adenylate cyclase  
 Interestingly, both lineage 5 and lineage 6 had mutations in genes encoding adenylate 
cyclases, though the affected genes were different between the two lineages. Adenylate cyclase 
makes cyclic AMP (cAMP), an important cell signaling molecule. Deletion of one of the 17 
adenylate cyclases in M. tuberculosis, Rv0386, reduces virulence and alters the immune 
response [209]. Bentley et al. found that this gene was a pseudogene in M. africanum 
GM041182. Although this mutation was lineage 6-specific, lineage 2 also had several strains in 
which Rv0386 was a pseudogene, suggesting that loss of this particular adenylate cyclase is 
unlikely to explain the geographical restriction of M. africanum (Supplemental Tables 5-S5 and 
5-S7). However, lineage 5 had nonsynonymous mutations in two adenylate cyclases, Rv1320c 
and Rv1647, both of which were predicted by SIFT to affect protein function [101]. Lineage 6 
had a lineage-specific insertion in Rv1264, and nonsynonymous mutations in two other 
adenylate cyclases, although these mutations were tolerated according to SIFT. In contrast, 
lineages 2 and 3 had no nonsynonymous mutations that were in an adenylate cyclase, while 
lineage 1 had one synonymous and one nonsynonymous mutation predicted to not affect 
protein function (Table 5-5). Thus, there may be differences in cAMP signaling within lineages 5 
and 6, particularly lineage 5, which could impact how this lineage interacts with the host. 
5.4.6.7 Mutations in drug resistance-associated genes 
Although we found that lineage 6 evolves drug resistance through similar mechanisms 
to lineages 2 and 4 (Figs 1 and S1), lineage 6 appears to evolve drug resistance at lower rates, 
and so we hypothesized that there may be mechanisms that could prevent the development of 
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resistance. Thus, we screened our lineage-specific SNPs to identify mutations in genes 
associated with drug resistance [149,189]. Interestingly, lineage 6 had two lineage-specific 
nonsynonymous mutations in rpoB, the gene that confers resistance to rifampicin when 
mutated in specific regions, and one lineage-specific nonsynonymous mutation in embC, a gene 
that can confer resistance to ethambutol when mutated (Supplemental Figures 5-S1a and 5-S1c, 
Table 5-5, Supplemental Tables 5-S5 and 5-S9). Lineage 1 and 3 also had lineage-specific 
mutations in embC but no other lineage had a lineage specific nonsynonymous mutation in 
rpoB. Both of the rpoB mutations were predicted to be tolerated by SIFT and do not confer drug 
resistance, but may have an effect on the development of resistance conferring mutations in 
rpoB, helping to explain the decreased rate of MDR in lineage 6 [101]. In addition, lineage 5 had 
nonsynonymous mutations in genes encoding AtpH (Rv1307) and AtpG (Rv1309), both of which 
are subunits of ATP synthase [210] (Supplemental Table 5-S5). Both of these mutations were 
predicted to affect protein function by SIFT [101]. ATP synthase is a target of bedaquiline, a new 
antibiotic reserved for the treatment of drug resistant tuberculosis [211].  
5.5 Discussion 
Our study describes the largest collection of sequenced lineage 6 isolates to date, and, 
to our knowledge, the first in depth analysis of the genetics of lineage 5. Through our work, we 
have characterized the genetic basis of antibiotic resistance in lineage 6 strains from Mali, 
shown that M. africanum and M. tuberculosis are part of the same species that exhibit similar 
intra-lineage diversity, and better defined the mutations and changes in gene content that typify 
these lineages. Collectively, this work provides insights into these understudied lineages and 
provides hypotheses as to why they are geographically restricted. 
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We evaluated 92 Mali MTC isolates using both assembly and alignment based 
approaches. Our assemblies revealed several new regions of difference and our alignments 
identified smaller lineage-specific changes. In addition, we found that not only is M. africanum 
not its own species, but some M. africanum-M. tuberculosis pairs of strains are more closely 
related than some pairs of strains from the same lineage. This emphasizes the extremely close 
relationship between all MTC lineages, highlighting the role that small changes within the MTC 
have played in altering host preferences and geographical restriction.  
In addition, we found that in Mali, M. africanum-associated and M. tuberculosis-
associated strains evolved antibiotic resistance through similar mutations. This adds support to 
the hypothesis that these strains are undergoing similar evolutionary pressures in Mali. 
Furthermore, we found a gidB polymorphism not previously described which may account for 
much of the streptomycin resistance in Mali. 
One hypothesis for the geographic restriction of lineages 5 and 6 is that they are less fit, 
either for transmission or in-host virulence. Several papers have shown no difference in 
transmission rates between M. tuberculosis-associated strains and M. africanum-associated 
strains [136,140,212,213]. Our Mali collection revealed three pairs of lineage 6 strains separated 
by 10 or fewer SNPs when aligned to M. tuberculosis H37Rv suggesting recent transmission of 
strains between patients [185]. One transmission event was between two HIV negative patients, 
one was between two HIV positive patients and one between an HIV positive patient and an HIV 
negative patient, suggesting that a compromised immune system is not required for a 
transmission event. However, all but one patient in our collection was native to Mali, so the 
ability to transmit may be specific to ethnic backgrounds prevalent in Mali. Furthermore, our 
ANI data demonstrated that there is comparable diversity in lineages 4 and 6, suggesting that 
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lineage 6 has not obviously undergone selective pressures that were not also experienced by 
other lineages in this region. Thus, our genomic study did not find evidence of reduced 
transmission or diversity as might be expected if lineages 5 and 6 were less fit to cause disease 
and transmit among people within this region of the world. 
Loss of fitness could also result either in an inability to succeed as well as other lineages 
outside of West Africa, or it could lead to an inability to grow in hosts not of West African 
ethnicity. It has been hypothesized that M. africanum is less virulent within both humans, mice 
and guinea pigs than is M. tuberculosis [138,140-142]. As a result, we looked for polymorphisms 
in known virulence genes. Our results showed that although lineage 6 contains lineage-specific 
mutations in genes previously shown to be required for growth in vitro, in macrophages, and in 
mice, it is not enriched for mutations in these categories compared to lineages 1, 2 and 3. This 
suggests that this lineage is not geographically restricted because of an overall numerical loss of 
virulence or growth-associated genes. 
Although there were no enrichments for mutations in these pathways, individual 
mutations can still greatly affect disease outcome, and analysis of our lineage-specific mutations 
identified several potential mechanisms that could lead to changes in how lineage 5 and 6 
proliferate and cause disease. Since our assemblies were of very high quality, we were able to 
observe changes in genes that previous studies could not, thus providing a prioritized list of 
these genes for investigating lineage 5 and 6 characteristics. One of these mechanisms involves 
alterations of proteins exposed to the immune system, especially those involved in ESX 
secretion, which may explain the altered response to ESAT-6 in patients infected by lineage 6 
[136]. Mycobacteria have five ESX secretion systems, also known as type VII secretion systems, 
which secrete small proteins across the bacterial cell envelope [214,215]. These secretion 
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systems are important to mycobacterial virulence. For example, ESX-1 secretion is lost as part of 
RD1 in M. bovis BCG vaccine strains, resulting in loss of ESAT-6 and CFP-10 secretion, and thus 
attenuation of the bacterium [216,217]. Thus, ESX secretion systems and their substrates play a 
crucial role in the interaction with the host immune system. We identified lineage-specific 
mutations in ESX genes in every lineage, indicating that each lineage may interact uniquely with 
the host immune system. Together, these mutations could lead to alterations in the pathogen-
host immune interaction, resulting in a requirement for the West African immune system.  
Genes involved in bacterial growth, including genes in the MCE operons and L,D-
transpeptidases, also contained lineage 5 and 6-specific mutations. The MCE operons play an 
important role in the virulence of M. tuberculosis, particularly in mycobacterial growth in 
macrophages [188,205]. Lineages 5 and 6 contained mutations affecting the function of proteins 
in both operons 1 and 3, suggesting potential defects in growth within the host. Similarly, L,D-
transpeptidases are critical to the structure of mycobacterial peptidoglycan, and loss of these 
enzymes affects bacterial structure and growth [204]. Two of the five L,D-transpeptidases in M. 
tuberculosis contained lineage 6-specific mutations affecting protein function, and one of these 
was also mutated in lineage 5, providing a possible explanation for the reported changes in cell 
size and doubling time in M. africanum GM041182 compared to M. tuberculosis H37Rv [138]. 
In addition, mutations in molybdenum and cobalamin metabolism and cAMP signaling 
could result in an altered niche for these lineages. The MTC has an expanded set of genes 
involved in molybdenum cofactor biosynthesis, which is involved in anaerobic respiration and 
the stress response, suggesting an important role for this cofactor in the evolution and biology 
of mycobacteria [207,218]. Likewise, vitamin B12 synthesis, which is found only in select 
mycobacteria, has specifically evolved in mycobacteria, which also have a transport system for 
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this vitamin, suggesting a crucial role for vitamin B12 in M. tuberculosis infection [208,219,220]. 
Thus, the presence of pseudogenes and lineage-specific non-synonymous SNPs that affect 
protein function in the synthesis of these cofactors in lineages 5 and 6 suggest that these strains 
are adapted for a different niche than lineages 1-4. In line with this, M. tuberculosis encodes 17 
adenylate cyclases, emphasizing the importance of this molecule to the bacteria [221], but both 
lineages 5 and 6 contained lineage-specific mutations that affected the protein function of 
several adenylate cyclases, suggesting altered cAMP signaling in these strains.  
 In addition, we saw high variability in PE, PPE and PE-PGRS genes, including changes in 
gene content. These repetitive regions are difficult to sequence and so are often ignored, but 
may play a crucial role in antigenicity and the host-pathogen interaction [86,222]. However, 
using our high quality assemblies and alignments, we were able to identify lineage-specific 
mutations in these genes, as well as changes in gene content. These mutations highlight the 
possibility of a critical role in host-pathogen interactions and emphasize the need for a more 
detailed analysis of these regions. Furthermore, there were also a number of mutated 
hypothetical proteins and proteins of unknown function, all of which may play a critical as yet 
undiscovered role. Both repetitive genes and hypothetical proteins require further follow-up to 
elucidate their role in the differences between lineages. 
A third hypothesis for the geographical restriction of lineages 5 and 6 is the presence of 
an unknown non-human reservoir. Indeed, M. africanum has been found in animals, including 
monkeys, cows, pigs and hyrax [223-228]. Unfortunately, given genomic data from human 
clinical isolates alone, we cannot address this hypothesis directly. However, given the similar 
level of diversity between lineage 4 and 6 in Mali and the evidence of person-to-person 
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transmission, even if lineage 6 has an animal reservoir, it is also well adapted to spread in 
humans living in this geographic setting.  
One weakness of our study was that we were limited in our sample size for lineage 5 
and M. bovis strains. Our collection was not representative of M. bovis genomic diversity, as 
three of the four M. bovis strains in our analysis were M. bovis BCG strains, which are 
attenuated lab strains used for vaccines. However, we only used the M. bovis strains in our ANI 
and gene content analysis, and required that any observations be consistent with wild-type M. 
bovis sequence, AF2122/97. Our results corroborated all previous findings of regions of 
difference, providing support that using BCG strains did not grossly alter our conclusions. 
Another weakness was that since all lineage 5 and 6 isolates in our study, except M. africanum 
GM041182, came from Mali, some of our observations may be specific to Mali. In fact, all of our 
patients were born in Mali, with the exception of one Central African patient infected with a 
lineage 4 strain. However, our lineage 6 isolates were genetically diverse and represented 
multiple different spoligotypes. In addition, our Mali isolates from other lineages did not cluster 
separately from strains from South Africa. Thus, while some of our conclusions may not apply 
outside of Mali, our collection reflected substantial diversity and did not originate from a clonal 
outbreak. 
This collection provides valuable insights into the distinguishing genomic features of M. 
africanum. Here, we have shown that lineage 6 in Mali appears able to spread through person-
to-person transmission and has diversified as well as lineage 4. Furthermore, we did not identify 
an increased rate of mutation in virulence-associated genes, also partially ruling out the 
hypothesis of decreased virulence and loss of fitness. In addition, we have identified several 
potential mechanisms for the geographical restriction of lineages 5 and 6, which provide a guide 
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to future studies focusing on the effects of specific genes. Future work can use these 
observations to inform experiments on mycobacterial pathogenicity and virulence, particularly 







Figure 5-1. M. africanum and M. tuberculosis drug resistance is genetically similar. 
 A) SNP-based phylogenetic tree of newly sequenced strains from Mali, constructed using 
FastTree [180]. B) Groups differing by 10, 20, 30, or 50 SNPs are shown with light grey bars, as 
calculated in Cohen et al. [154]. C) Comparison of genotypic and phenotypic DST (drug 
susceptibility testing). Genotypic drug resistance was calculated using HAIN genetic markers 







Figure 5-2. Phylogenetic tree of assembly collection.  
Nodes, lineages, and Mali strains are indicated. All key nodes separating the major lineages had 
bootstrap values of 100%, except for the node separating M. tuberculosis lineage 1 and M. 
africanum lineage 5, which had a bootstrap value of 83%.  
 
 
Figure 5-3. Average nucleotide identity (ANI) analysis indicates M. africanum and M. 
tuberculosis are not separate species.  
A) ANI values when comparing M. africanum and M. tuberculosis do not cross the ANI species 
threshold of 94-95%. In fact, this comparison shows that the distribution of M. africanum/M. 
tuberculosis comparisons (red) overlaps that of inter-lineage M. tuberculosis comparisons 
(purple), indicating that M. africanum should be considered another lineage of M. tuberculosis. 
B) Similarly, ANI values when comparing M. bovis and M. tuberculosis also overlap with inter-
lineage M. tuberculosis, and indicate that M. bovis should also be considered another lineage of 
M. tuberculosis. C) ANI values comparing M. africanum and M. bovis (pink) also overlap inter-




Figure 5-4. Diversity in Mali lineage 4 and lineage 6 strains diversity.  
ANI values for comparisons (A) within all Mali lineage 4 isolates and (B) within all lineage 6 





Figure 5-5. Percentage of lineage-specific mutations in virulence associated genes.  
A) Percentage of lineage-specific mutations in coding sequences of the genes in each category. 
Sassetti virulence genes are genes that were identified in [187] as being required for virulence in 
mice. TraSH essential and slow growth genes were identified by Sassetti et al. under in vitro 
conditions [186]. Rengarajan macrophage genes were identified by Rengarajan et al. as being 
required for growth in macrophages [188]. Comas antigen genes were genes identified as 
containing T cell epitopes [135]. The color of the bar indicates type of mutation. B) Percentage 
of lineage-specific pseudogenes falling into the above defined categories. TraSH virulence genes 
and Comas antigen genes had no pseudogenes in any lineage. Lineage is indicated by the 













Negatives Sensitivity Specificity F 
Total 
strains 
rifampicin 28 4 2 58 87.50% 96.67% 90.32% 92 
isoniazid 40 2 1 49 95.24% 98% 96.39% 92 
ethambutol 19 9 3 61 67.86% 95.31% 76% 92 
streptomycin 0 35 0 57 0% 100% 0% 92 
 
Table 5-1. Genotypic drug resistance analysis. 
Table showing true positives, false positives, true negatives, false negatives, sensitivity, and 




A:  root node of lineage 6     
  loss annotation RD 
  Rv0124 PE-PGRS family protein PE_PGRS2 RD701 
    B:  root node of lineage 6 and M. bovis   
  loss annotation RD 
  Rv0222 enoyl-CoA hydratase EchA1 RD10 
  Rv1965 ABC transporter permease YrbE3B RD7 
  Rv1966 MCE-family protein Mce3A RD7 
  Rv1967 MCE-family protein Mce3B RD7 
  Rv1968 MCE-family protein Mce3C RD7 
  Rv1969 MCE-family protein Mce3D RD7 
  Rv1970 MCE-family lipoprotein LprM RD7 
  Rv1971 MCE-family protein Mce3F RD7 
  Rv1972 MCE-associated membrane protein RD7 
  Rv1973 MCE-associated membrane protein RD7 
  Rv1974 membrane protein RD7 
  Rv1975 hypothetical protein RD7 
  Rv1976c hypothetical protein RD7 
  Rv3617 epoxide hydrolase EphA RD8 
  Rv3618 monooxygenase RD8 
  Rv3619c ESAT-6 like protein EsxV RD8 
  Rv3620c ESAT-6 like protein EsxW RD8 
  Rv3621c PPE family protein PPE65 RD8 




  gained annotation RD 
  
Orthogroup 850447630 Hypothetical protein (has 2 domains: 104 kDa 
microneme/rhoptry antigen & large tegument protein UL36)   
  Orthogroup 850450572 PE-PGRS family protein   
    C:  root node of lineage 5     
  loss annotation RD 
  Rv1334 hydrolase RD711 
  Rv1335 sulfur carrier protein CysO RD711 
  Rv1523 methyltransferase   
  Rv1978 hypothetical protein RD713 
  Rv1979c permease RD713 
  Rv1993c hypothetical protein RD743 
  Rv1994c ArsR family transcriptional regulator CmtR RD743 
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  Rv1995 hypothetical protein RD743 
  Rv3514 PE-PGRS family protein PE_PGRS57   
    D:  root node of lineages 5 and 6 and M. bovis   
  loss annotation RD 
  Rv2073c oxidoreductase RD9 
  Rv2074 pyridoxamine 5'-phosphate oxidase RD9 




  gained annotation RD 
  Orthogroup 850451604 PPE family protein   
 
Table 5-2: Orthologs identified in gene content analysis as lost or gained at nodes A-D.  
For some RDs, the first and/or last gene in the region was not identified in our analysis because 
enough of the gene remained to align to H37Rv, and thus was not considered absent. Nodes A-D 
were identified in Fig. 2. 
 
lineage shared hits our analysis only Bentley analysis only 
LIN-1 NA 5 NA 
LIN-2 NA 23 NA 
LIN-3 NA 5 NA 
LIN-4 0 0 3 
LIN-6 5 3 27 
Maf 5 0 8 
 
Table 5-3. Table comparing the pseudogenes identified in our study to those identified by 




  Mutations Pseudogenes 






















1 99.5 ± 28.8 0 




681 201.5 ± 26.4 8 
LIN-5 and LIN-6 
2600.4 ± 
80.5 
90 200.5 ± 25.4 5 




0 148.4 ± 55.4 0 
LIN-1, LIN2, and LIN-3 
1803.4 ± 
161.9 
NA 182.3 ± 42.5 NA 
 
Table 5-4. Summary of the lineage-specific mutations and pseudogenes detected for each 
lineage.  






























Indel 0 0 0 1 0 0 
Synonymous 3 0 1 2 1 0 
Non-












Indel 1 0 0 1 0 0 
Synonymous 2 0 0 2 0 0 
Non-












Indel 0 0 0 0 0 0 
Synonymous 2 0 2 1 2 1 
Non-












Indel 3 0 1 1 0 0 
Synonymous 10 0 0 7 2 1 
Non-












Indel 2 0 0* 0 1 0 
Synonymous 1 0 1 7 0 0 
Non-
















Indel 0 0 0 2 0 0 
Synonymous 2 0 0 0 0 0 
Non-





function 0 0 1 0 0 0 
 
Table 5-5. Summary of lineage-specific mutations of highlighted in 5.4.6.  
Each heading refers to the results section these mutations are discussed.  
Supplementary files 
 
S1 Figure. Mutations in drug-resistance associated genes. Plots showing details of known drug 
resistance mutations present for each drug. Light blue or red horizontal shaded bars indicate 
phenotypic sensitivity or phenotypic resistance for the strain of interest. The corresponding vivid 
color in a particular box indicates the presence of the resistance mutation represented by that 
column. A) rifampicin B) isoniazid C) ethambutol D) streptomycin 
 
S1 Table. Samples used in our study. A) List of Mali samples used in our study, with patient 
information. B) List of all 137 strains used for our assembly-based analyses, including 91 newly 
sequenced strains from Mali, 40 strains from the K-RITH collection from South Africa [154], and 
six strains from Genbank. C) Sequence Read Archive identifiers for each of the 161 additional 




S2 Table. Drug resistance analysis. A) Drug resistance mutations analyzed. B) Table showing 
true positives, false positives, true negatives, false negatives, sensitivity, and specificity for the 
four drugs for which we have phenotype information for all strains. 
 
S3 Table. Lineage-specific mutations. All lineage-specific mutations (A) in coding sequences and 
(B) in intergenic regions. Maf indicates mutations shared between lineage 5 and 6 but not found 
in lineages 1-4. No mutations were shared between lineages 1-4 but not lineages 5-6. 
 
S4 Table. Lineage-specific pseudogenes. Maf indicates mutations shared between lineage 5 and 
6 but not found in lineages 1-4. No mutations were shared between lineages 1-4 but not 
lineages 5-6. 
 
S5 Table. Comparison of pseudogenes to previous analysis. A) Comparison of pseudogenes 
identified differently by our study to those identified by Bentley et al [148]. This table compares 
lineage 4, lineage 6 or M. africanum-specific pseudogenes identified in our study to 
pseudogenes identified by Bentley et al. as belonging to lineage 4, lineage 6, lineage 6 and 
animal strains or lineage 5, -6 and animal strains. A “0” indicates that the gene is not a 
pseudogene in that strain, while “1” indicates that it is, and “2” indicates an ambiguous call. 
Genes with a light blue background were identified in this study and not by Bentley et al., while 
genes with a light green background were identified by Bentley et al., but not by this study, and 
genes with a purple background were identified by both studies. B) Table summarizing the 




Legends for Supplemental Figures 
Supplemental Figure 3-S1. Changes in gut microbiota gene expression with mycobacterial 
infection. 
Heatmaps of log2 fold-change and adjusted P-value compared to Day -3 for A) Balb/c, B) Black/6, 
C) RAG-/-  and D) MyD88-/-. All KEGG orthologs significant in at least one time-point are included. 
E) Shows the overlap between these groups. 
 
Supplemental Figure 5-S1. Mutations in drug-resistance associated genes.  
Plots showing details of known drug resistance mutations present for each drug. Light blue or 
red horizontal shaded bars indicate phenotypic sensitivity or phenotypic resistance for the strain 
of interest. The corresponding vivid color in a particular box indicates the presence of the 
resistance mutation represented by that column. A) rifampicin B) isoniazid C) ethambutol D) 
streptomycin 
 
Legends for Supplemental Tables 
Supplemental Table 2-S1. Differentially abundant OTUs in pre-infected samples and post-
infected samples. 




Supplemental Table 2-S2. Differentially abundant OTUs in uninfected and infected samples. 
A q-value cutoff of q<0.01 was used. 
 
Supplemental Table 3-S1. OTUs and KEGG orthologs associated with M. tuberculosis colony 
forming unit (CFU) counts. 
Analysis indicates which form of sequencing was used to calculate the relative abundance of the 
feature and organ indicates which organ the feature was associated with. A cutoff of Q<0.05 
was used for this table. 
 
Supplemental Table 3-S2. OTUs and KEGG orthologs associated cytokine levels. 
Analysis indicates which form of sequencing was used to calculate the relative abundance of the 
feature, cytokine and organ indicates which cytokine and organ the feature was associated with. 
A cutoff of Q<0.05 was used for this table. 
 
Supplemental Table 3-S3. OTUs identified through 16S rDNA sequencing significantly 
associated within infecting organism. 
Y=yes, N=no, NA=not applicable. A cutoff of Q<0.05 was used for this table. 
 
Supplemental Table 3-S4. OTUs identified through whole genome sequencing significantly 
associated within infecting organism. 
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Y=yes, N=no, NA=not applicable. A cutoff of Q<0.05 was used for this table. 
 
Supplemental Table 3-S5. KEGG orthologs identified through 16S rDNA sequencing 
significantly associated within infecting organism. 
Y=yes, N=no, NA=not applicable. A cutoff of Q<0.05 was used for this table. Outliers removed 
from these results. 
 
Supplemental Table 3-S6. KEGG orthologs identified through whole genome sequencing 
significantly associated within infecting organism. 
Y=yes, N=no, NA=not applicable. A cutoff of Q<0.05 was used for this table. 
 
Supplemental Table 3-S7. KEGG orthologs identified through RNA sequencing with significant 
change in expression compared to pre-infection in at least one post-infection timepoint. 
A cutoff of adjusted P <0.05 in at least one timepoint was used for this table. 
 
Supplemental Table 5-S1. List of Mali samples used in our study, with patient information. 
 
Supplemental Table 5-S2. List of all 137 strains used for our assembly-based analyses. 
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Includes 91 newly sequenced strains from Mali, 40 strains from the K-RITH collection [154], and 
six strains from Genbank. 
 
Supplemental Table 5-S3. Sequence Read Archive identifiers for each of the 161 additional 
strains used in our SNP analysis. 
 
Supplemental Table 5-S4. Drug resistance mutations analyzed. 
 
Supplemental Table 5-S5. All lineage-specific mutations in coding sequences. 
 
Supplemental Table 5-S6. All lineage-specific mutations in intergenic regions. 
 
Supplemental Table 5-S7. Lineage specific pseudogenes. 
 
Supplemental Table 5-S8. Comparison of pseudogenes identified differently by our study to 
previous analysis. 
This table compares lineage 4, lineage 6 or M. africanum specific pseudogenes identified in our 
study to pseudogenes identified by Bentley et al. [148] as belonging to lineage 4, lineage 6, 
lineage 6 and animal strains or lineage 5, -6 and animal strains. A “0” indicates that the gene is 
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not a pseudogene in that strain, while “1” indicates that it is, and “2” indicates an ambiguous 
call. Genes with a light blue background were identified in this study and not by Bentley et al., 
while genes with a light green background were identified by Bentley et al., but not by this 
study, and genes with a purple background were identified by both studies. 
 
Supplemental Table 5-S9. Lineage-specific mutations of highlighted in 5.4.6.  
Each heading refers to the results section these mutations are discussed. For full list of lineage-
specific mutations, see Supplemental Table 5-S5.  
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